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ABBREVIATIONS 
AUC: area under curve 
BMT: benign mammary tumor 
BSA: bovine serum albumin 
DAB: 3,3’-diaminobenzidine 
ddH2O: double distilled water 
DEPC: diethylpyrocarbonate 
DTT: dithiothreitol 
EDTA: ethylenediaminetetraacetic acid 
ELISA: enzyme-linked immunosorbent assay 
FS: final score (for immunohistochemistry scoring) 
IHC: immunohistochemistry 
IMAC:  immobilized metal ion affinity chromatography 
IPTG: isopropylthio-β-galactoside 
IS: intensity score (for immunohistochemistry scoring) 
LB: lysogeny broth 
MGT: mammary gland tumor 
MMP-2: matrix metalloproteinase 2 
MMP-9: matrix metalloproteinase 9 
MMP-9-Dist: distal part of MMP-9 
MMP-9-Prox: proximal part of MMP-9 
NGAL: neutrophil gelatinase-associated lipocalin 
MMT: malignant mammary tumor 
OD: optical density 
SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis 
PBS: phosphate buffered saline 
PBS-T: phosphate buffered saline tween-20 
PCR: polymerase chain reaction 
PS: proportion score (for immunohistochemistry scoring) 
RT: Reverse transcription 
TAE: tris acetate EDTA 
TIMPs: tissue inhibitors of metalloproteinases 
TMB: tétraméthylbenzidine  















- 20 - 
 
  
- 21 - 
 
 
Mammary gland tumors are the most common type of tumors in female dogs, with an 
incidence higher than 25% in unsprayed females. This incidence is more than three times 
higher than the one of breast cancer in human medicine. Constant research projects are lead to 
find new ways to diagnose, evaluate, follow-up and treat this pathology in both species. 
Matrix metalloproteinase 9 (MMP-9), also known as gelatinase B, is a major contributor to 
the proteolytic degradation of extracellular matrix during tumor invasion. In human breast 
cancer research studies, this protein was shown to be highly expressed in the serum, the blood 
and the mammary gland histological tissue of breast cancer patients and several authors have 
suggested the use of MMP-9 as a biomarker of breast cancer. 
Neutrophil gelatinase-associated lipocalin (NGAL) was first isolated in 1992 as a small 
glycoprotein bound with a covalent link to MMP-9 in human neutrophils. It was later showed 
that NGAL can protect MMP-9 from degradation and that it was also a valuable biomarker of 
breast cancer disease in the urine, serum and mammary tissue of human patients. 
Very few research projects in veterinary medicine have aimed to investigate the correlation 
between canine mammary gland tumor and the two proteins. Only few studies have reported 
the use of anti human-MMP-9 antibodies in immunohistochemical staining of canine 
mammary gland tissue and it was demonstrated that its expression was significantly correlated 
with several prognostic factors such as malignancy status, histological grade, lymph node 
metastases and lower disease-free survival. No report has been made concerning NGAL and 
its correlation with any canine tumor. 
After a short bibliographic review on the findings made concerning NGAL and MMP-9 in 
both human and veterinary medicine, the aim of this study was to use canine specific anti -
NGAL and anti MMP-9 antibodies to evaluate the expression of the two proteins in different 
biologic samples from patients suffering from at least one mammary tumor. Blood serum and 
urinary NGAL expression was analyzed by enzyme-linked immunosorbent assay (ELISA) 
while both NGAL and MMP-9 expression in mammary gland tissue sections was evaluated 
by immunohistochemistry (IHC) after formalin fixation. 
This study was performed at the Microbiology and Public Health Department of Chung-Hsing 
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1. MATRIX METALLOPROTEINASE 9 
 
 
1.1. Introduction to MMPs 
 
The extracellular matrix is constantly degraded, repaired and remodeled and this phenomenon 
is essential for the embryonic development, the morphogenesis or the tissue repairs. Several 
types of proteinases play an important role in the degradation of this extracellular matrix but 
the major ones are believed to be the matrix metalloproteinases, also called MMPs (Visse et 
al.,2003).  
 
Humans have 23 different MMPs but the activity of most of them is very low in normal 
tissues. Their expression is under the influence of many factors such as inflammatory 
cytokines, growth factors, hormones or cell-matrix. All MMPs are secreted as inactive pro-
enzymes. Their proteolytic activities are precisely regulated by the activation from the 
precursor and by inhibition with endogenous inhibitors, mainly tissue inhibitors of 
metalloproteinases, also known as TIMPs and α2-macroglobulin (Nagase et al., 1999). 
 
 
1.2. MMP-9 general structure  
 
Most MMPs, including MMP-9, contain a propeptide, a catalytic metalloproteinase domain 
with a zinc binding motif, a hinge region (linker), and a hemopexin domain.  The arrangement 
of those typical domains, the presence of other domains and the substrate preferences lead to 
the separation of the MMPs in different groups such as collagenases, gelatinases, matrilysins 
and others. 
 
Gelatinases, which include MMP-2, known as gelatinase A, and MMP-9, known as gelatinase 
B, can digest a large number of extracellular matrix molecules such as gelatin, type IV, V and 
XI collagens, elastin, laminin, aggrecan core proteins (Nagase et al., 2006). They are 
recognized by the three repeats of a fibronectin type II motif they have in the middle of their 
catalytic domain (figure 1). This particular domain helps them to bind the gelatin or collagen 
in order to digest it. Unlike MMP-2, MMP-9 is not able to digest type I, II and III collagens.  
 
The role of the hinge region is still unclear, but the hemopexin domain seems to mediate 
many inter-protein interactions. It plays a role in the binding of the TIMPs, in the activation of 
the protein, in the binding of some substrates and also in the homodimerization of MMP-9 
(Cha et al., 2002).  
 
Human MMP-9 is constituted by 707 amino-acid residues while canine MMP-9’s sequence is 
3 amino-acids shorter (NCBI Protein Data Bank). 
 

















Figure 1b: NCBI Protein Data Bank (PDB) rendering of human MMP-9 
 
Figure 1: Architectural organization of human MMP-9 
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1.3. Regulation of MMP-9 activity 
 
In order to avoid undesired matrix damage, the activity of such proteins has to be accurately 
controlled. This control is mainly mediated by the activation of the pro-enzyme and the 
inhibition of the active enzyme by endogenous inhibitors. 
 
• Activation of pro enzyme 
 
MMP-9 is synthesized as a pro-enzyme. The signal peptide is removed during the translation 
step and pro-MMP-9 is secreted, mainly from inflammatory cells such as neutrophils, 
monocytes/macrophages and mast cells but lower expression intensity can be found in 
epithelial and endothelial cells, fibroblasts and sometimes hematopoietic cells. However, this 
pro-enzyme is inactive. At one end of the pro-MMP-9 is the pro-peptide domain which allows 
the enzyme to be active after it has been cleaved by a complicated activation network cells 
(Opdenakker et al., 2002). It would seem that the pro-MMP-9 can also be activated by other 
mechanisms: for instance, neutrophils have been shown to activate the enzyme via an 
oxidative mechanism (Peppin et al., 1986). Overall, all the mechanisms that lie behind the 
activation of MMP-9 are still unclear and it must be noted that some findings also revealed 
that the pro-MMP-9 could in some cases display significant catalytic activity in the presence 
of the propeptide (Bannikov et al., 2002). 
 
• Inhibitors of MMP activity 
 
Many naturally occurring gelatinase inhibitors have been studied. The most important ones 
are mainly α2-magroglobulin and tissue inhibitor of metalloproteinase also known as TIMPs. 
α2-macroglobulin is a relatively large protein that is abundant in the serum and is able to bind 
to the active form of the enzyme (Morodomi et al., 1992). TIMPs form a large family of small 
proteins, containing around 170-180 amino acids, that can form a high-affinity complex with 
metalloproteinase and in particular with MMP-9 (Egeblad et al., 2002). The complex formed 
by the inhibitor and the MMP-9 are internalized into the cells and is degraded. 
Unlike the other collagenase MMP-2, MMP-9 expression is highly inducible under the 
influence of many factors such as growth factors, chemokines, and a wide array of other 
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1.4. Physiological roles of MMP-9 
 
MMP-9 plays a wide array of roles in many different physiological processes such as growth 
and development, immune modulation, inflammatory status, wound healing and several more.  
MMP-9 was shown to play very important physiological roles as early as in the embryonic 
development stages. It was shown to be highly expressed in the mouse embryo (Alexander et 
al., 1996). However, MMP-9 knocked out mice were viable but showed developmental 
abnormalities. Its main effects have been noticed in particular on the vascularization and 
ossification as the knockout resulted in skeletal abnormalities, mainly a delayed ossification 
of the growth plate in long bones as MMP-9 was shown to be a key regulator of growth plate 
angiogenesis and apoptosis of chondrocytes (Vu et al., 1998). Although MMP-9 is highly 
expressed in immune cells such as neutrophils, no important immune-related abnormality was 
reported in the knocked-out mice.  
 
Reproduction is also a domain in which MMP-9 seems to be important. In particular, it has 
been suggested to be involved at different phases of the cyclic changes in female 
reproduction, mainly in the menstrual cycle (mostly the matrix remodeling during the cycle), 
the ovulation, the embryo implantation, the parturition (degradation of the extracellular matrix 
of the fetal membranes to facilitate their rupture), and even the involution of the mammary 
glands after the lactation (Vadillo-Ortega et al., 1995; Jeziorska et al., 1996). MMP-9 
deficiency was also proven to impair reproduction as Dubois and coworkers showed that 
MMP-9 knockout mice led to a higher percentage of infertile breeding pairs, a smaller number 
of litters and a smaller size of the litters (Dubois et al., 2000). 
 
Leukocytes need to adhere to the endothelium of the blood-vessels to reach the targeted 
tissue. They use large amounts of protease-containing granules, which are rapidly delivered to 
the cell surface and secreted into the extracellular milieu. One of these granules was named 
gelatinase granule as it contained a high amount of MMP-9 (Kjeldsen et al., 1994). 
 
MMP-9 plays an important role in wound healing and in coordinating epithelial regeneration 
in general. For instance, it was shown in vitro that the keratinocyte migration was dependent 
on induction of MMP-9 and is impacted by blocking the protein with a specific antibody or 
with a general MMP inhibitor (McCawley et al., 1998). The role of MMP-9 in wound healing 
is yet unclear as it participates with several other MMPs in the inflammation stage (regulation 
of chemokine activity, establishment of chemotactic gradients, extravasation of leukocytes 
into the injured tissue…) and the epithelial repair stage of wound healing (Gill et al., 2008).  
MMP-9 was also shown to play significant roles in angiogenic revascularization of ischemic 
tissues (Johnson et al., 2004), or remyelination (Larsen et al., 2003). 
 
MMP-9 shows a wide physiological function panel but an increase of its activity has also been 
reported in several pathological status, such as cancer, inflammatory or infectious diseases, 
vascular diseases and many more (Van den Steen et al., 2002), but the most important 
pathological roles it plays are most certainly in tumor progression. 
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1.5. MMP-9 in tumor progression 
 
To enter and exit vasculature at the primary and metastatic sites, metastatic tumor cells must 
cross the basement membranes. MMPs participate in several steps in tumor progression, such 
as invasion, metastasis and angiogenesis (Himelstein et al., 1995). MMP-9 has rapidly been 
associated with malignant tumor progression and metastasis by degradation of the matrix and 
to facilate tumor invasion into other tissues (MacDougall et al., 1995). 
 
Enhanced expression of MMP-9 has been observed in cancers of breast, colon, lung, skin, 
ovary, prostate… (Egeblad et al., 2002). For many of cancers, the increase in MMP-9 activity 
was often correlated with malignancy status, increased invasiveness and increased metastasis. 
The current view is that gelatinases, and in particular MMP-9, are needed at multiple stages 
during the tumor progression such as growth of the primary tumor, intravasation of tumor 
cells and invasion of the metastatic cells in the secondary organ (Björklund et al., 2005). 
Angiogenesis is also a stage of tumor invasion in which MMP-9 plays a significant role by 
triggering the angiogenic switch during carcinogenesis via the release of vascular epidermal 
growth factor (Bergers et al., 2000). 
  
- 30 - 
 
2. NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN 
 
 
2.1. The lipocalin family: a common tertiary structure for multiple and 
diverse functions 
 
The lipocalin family is a large group of extracellular proteins that are widely distributed in the 
living organisms. They can be found in animals, as well as in plants, and even in bacterias. 
The name lipocalin is derived from the Greek words kalyx and lipos. This etymology reveals 
two fundamental aspects of this family: their three dimensional structure that is in the shape of 
a kalyx, and their ability to bind various lipophilic ligands, ability which will determine many 
properties. 
 
The functions of those extracellular cup-shaped proteins are numerous and highly varied: 
pheromone activity, olfaction, regulation of immunological processes, coloration, cell 
regulation, developmental processes, reaction of organisms to various pathologies such as 
bacterial infections or tumoral processes and many more that remain unstudied until now 
(Grzyb et al., 2006). 
 
 
2.2. NGAL general structure  
 
Despite their low homology in the amino acid sequence, the lipocalins share a common 
tertiary structure and an overall folding pattern that is highly conserved and essential for their 
function.  The region determining the specific properties of the lipocalin is the kalyx. It is 
formed by nine β–strands, a large alpha helix and a much smaller one, with only three turns, 
called the 310-helix. Eight of the nine β–strands are not only linked by β–hairpin connections, 
but are also connected by transversal hydrogen bonds and are organized in an antiparallel way 
forming a β–sheet. This β-sheet is closed back on itself with hydrogen bonds to form a β-
barrel. The barrel has a closed end on one side and an open end which is the opening of the 
ligand-binding site and is partially closed by the Ω-loop, also known as the scaffold loop. The 
cavity inside the calyx is very rich in lipophilic amino acid residues, making the ligand-
binding site very hydrophobic, and explaining the lipophilic nature of the ligands (Flower et 
al., 19995, 1996). NGAL is made up with 178 amino-acid residues (Kjeldsen et al., 1993) and 
respects the typical lipocalin secondary and tertiary structures (figures 2, 3, and 4). 
  




Figure 2: Unfolded NGAL: simplified view of the typical lipocalin fold, orthogonal to the 
axis of the kalyx 
 
The antiparallel β-strands are labeled A-I and the α-helix is labeled α. The N-terminal 310-helix and the C-
terminal are also marked. Hydrogen bonds are marked by the grey lines. Strand A interacts with strand H, 






Figure 3: Simplified view of NGAL fold in the axis of the barrel (cross section) 
 
β-strands marked with an arrow pointing up have a strand direction out of the plane of the paper and those with 
an arrow pointing down are directed into the plane of the paper (according to Flower et al., 1996). 













Figure 4: NGAL’s calculated structure according to Coles et al. (1999) 
 
The view is orthogonal to the barrel axis.The β-strands of the two different β-sheets are shown in blue and green, 
the helix are labeled in red and the Ω-loop in orange. Note how C87 is projected into the solvent and is therefore 
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• Interaction site with MMP-9 
 
At the floor of the barrel, very close to Cys 87, three amino-acid residues (Asp 34, Glu 60, 
Asp 61) form a negatively charged patch. This site has been suggested to be the interaction 
site between NGAL and MMP-9, while the unpaired cysteine Cys87 forms the intermolecular 
disulphide bond between the two proteins (Coles et al, 1999). 
 
 
2.3. Physiological functions of NGAL 
 
First believed to be only transporters of small lipophilic molecules, lipocalins tend to prove 
that they fulfill many different biological functions, some potentially significant, such as 
immunomodulation (Kremer JM. et al, 1988), cell regulation (Nagashima M. et al, 2009), 
enzyme synthesis, olfaction and taste (Guiraudie G.et al, 2003), pheromones (Bacchini A. et 
al, 1992). NGAL, just like most of the other members of its family, shows a wide variety of 
these functions. 
 
• Iron capture and bacteriostatic effect 
 
Iron is a metal essential for microbial growth. However, when infecting a human person, they 
find themselves in a severely iron-poor environment as the estimated concentration of free 
iron in the human body is as low as 10-24 mol/L (Carrano et al, 1978). In response to this iron-
poor environment, microbes, in particular bacteria, have developed siderophores (Greek 
meaning “iron carrier proteins”). Siderophores are relatively low molecular weight proteins 
produced by microorganisms whose affinity for iron, especially ferric iron (Fe3+) is several 
times higher than the affinity of human endogenous iron-binding proteins. They can capture 
the iron from the surrounding environment and transport it back into the bacteria (Goetz et al., 
2002). 
 
NGAL has the ability to bind siderophores and to transport them inside the cells, preventing 
bacteria from acquiring the siderophore-bound iron they need. This mechanism is believed to 
underlie the main functions accredited to NGAL. Released by activated neutrophils, NGAL 
acts as a bacteriostatic agent and participates in the antibacterial iron-depletion strategy of the 
immune system (Goetz et al, 2002). The antibacterial function of NGAL was confirmed by 
Berger and colleagues in 2006: generated gene-targeted NGAL-deficient mice showed a 
significantly increased sensitivity to E.coli infection (Berger et al, 2006). 
 
However, this lipocalin is also expressed in aseptic diseases, implying that it may serve 
additional functions. 
 
• Management of intracellular iron concentration, specific cellular responses and role in 
cell apoptosis 
 
After fixation with its cell-membrane receptor, NGAL is up-taken intracellularly and is stored 
in an endosome. If it contains an iron molecule, it will deliver it, generating an increase in 
intracellular iron concentration promoting regulation of iron-responsive genes like ferritin and 
transferrin receptors (Yang et, 2002). However, if NGAL is free of any iron, it will bind to 
intracellular iron before being exocytised (figure 5). In this case, NGAL has an action 
opposite to the one it has if it contains iron, the regulation of iron-responsive genes is in the 
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opposite direction, and if the intracellular iron concentration is massively decreased, cell 
apoptosis can ensue. 
 
Ectopic expression of NGAL receptors on HeLa cells confered them the ability to undergo 
either iron uptake or apoptosis, depending on whether the ligand of NGAL was iron-loaded or 
iron-free. NGAL:siderophore:iron complex significantly increased the intracellular iron 
amount whereas NGAL:siderophore free of any iron molecule, generated a decrease in the 







Figure 5: Schematic depiction of NGAL cellular cycle  
 
The binding of NGAL with its receptor is followed by the internalization of NGAL and its ligand. Holo-NGAL 
can then release its iron molecule, inducing an increase in the intracellular ferric concentration and also 
regulating iron-dependent metabolic pathways. 
Apo-NGAL can also interact with the same receptors and be internalized. Once inside the cell, it can bind to the 
iron present inside the cytoplasm and be externalized, in the exact opposite way as previously described with 
holo-NGAL. The intracellular ferric concentration will therefore decrease (according to Bolignano et al, 2010). 
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• NGAL is a pro-inflammatory molecule and a neutrophil chemoattractant 
 
NGAL expression is strongly up-regulated in several inflammatory diseases: psoriasis 
(Mallbris et al, 2002), periodontitis, myocarditis (Yndestad et al, 2009), ischemia reperfusion 
injury (Lee et al, 2011) and ulcerative colitis (Galamb et al, 2008). 
While studying the mediation function of NGAL in immune responses to bacterial infection, 
it was observed that NGAL’s expression was massively increased in the serum, the liver and 
the spleen of the tested mice, six hours after an intraperitoneal injection of E.coli (Flo et al, 
2004). 
 
NGAL is suspected to be a neutrophil chemoattractant as the number of neutrophils recruited 
to infiltrate heart in a mice model of heart-transplant was shown to be significantly higher in 
wild type mice than in NGAL knocked-out mice (Aigner et al, 2007). However, NGAL 
precise functions and factors of regulation in the inflammatory processes remain unclear. 
 
 
• NGAL as a protective factor against oxidative stress 
 
NGAL seems to play an important role in the antioxidant machinery of the cells. The first sign 
of this aptitude came in 2008, when Roudkenar et al. revealed that NGAL acted as a 
protective factor against hydrogen peroxide (H202) toxicity. Using Chinese hamster ovary 
(CHO) cells, it was shown that the cell proliferation was higher in the CHO cells expressing 
NGAL compared to the control cells when H202 was added in the culture. Conversely, H202 
was more toxic to the cells for which NGAL’s RNA had been silenced (Roudkenar et al, 
2008). 
 
Experiments involving human embryonic kidney cells demonstrated that the NGAL 
expression had a significant modulation effect on the expression of heme oxygenase (HO1) 
and of superoxide dismutases (SOD 1 and SOD 2), which are both strong antioxidant 
enzymes. Overexpression of NGAL resulted in an upregulation of mRNA and protein 
translation of the enzymes, while silenced cells showed a diminution of the HO1 synthesis. 
Finally, the cells that were overexpressing NGAL were proven to be significantly more 
resistant in vitro to the strong oxidative stress due to the addition of hydrogen peroxide 
(Bahmani et al, 2010). 
 
 
• Role in development 
 
NGAL can mediate processes of growth, development and differentiation of several human 
tissues in the embryonic stages. Not only it was demonstrated that NGAL was a key 
participant in mesenchymal-epithelial transformation, due to its aptitude to increase cellular 
iron stores in the developing kidney (Yang et al, 2002) but, it was also shown that NGAL had 
more differentiation-inducing functions. In cultured collecting duct cells, hepatocyte growth 
factors stimulate epithelial cells to produce NGAL and when this expression was blocked by 
silencing RNAs, it induced cystic structures rather than correctly assembled tubules. These 
experiments demonstrated a regulatory role of NGAL in epithelial morphogenesis by 
mediating the organization of the cells (Gwira et al, 2005). 
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2.4. Function of NGAL in solid tumors 
 
The role of NGAL varies depending on the type of cancer. In some organs, the protein will 
tend to have a positive role in the protection of cancer cells, therefore allowing the tumor to 
grow and metastase. Examples of such tumors are thyroid carcinoma (Iannetti et al., 2008), 
endometrial carcinoma (Miyamoto et al. 2011) or breast cancer. However in other types of 
cancers, the protein can sometimes have a completely opposite role and help the body to 
defend against the tumor by reducing its growth, decreasing its invasiveness and tendency to 
metastase or by inhibiting angiogenesis. It was shown to be the case in colon (Lee et al., 
2006) and pancreatic cancers (Tong et al., 2008). 
 
 
2.5. Effect of NGAL on MMP-9 
 
Yan and co-workers showed by immunoprecipitation that NGAL could bind MMP-9 to form 
a complex. The formation of the complex was confirmed by in vitro reconstitution 
experiments by mixing the two proteins. Most interestingly, degradation of MMP-9 was 
significantly inhibited in the presence of NGAL and resulted in the preservation of its enzyme 
activity. This protective effect of NGAL was then confirmed in a cell-culture system in which 
forced expression of NGAL in human breast carcinoma cells resulted in an increase of MMP-
9 enzymatic activity independent of changes in MMP-9 gene translation. It was thereby 
proven that NGAL could modulate MMP-9 activity by protecting it from degradation (Yan et 
al., 2001). It was then suggested that the involvement of NGAL in tumor progression may be 
in part due to its protective effect on the matrix degrading enzyme. 
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3. USE OF MATRIX METALLOPROTEINASE 9, NEUTROPHIL 
GELATINASE ASSOCIATED LIPOCALIN AS BIOMARKERS IN 
MAMMARY GLAND TUMORS 
 
3.1 . MMP-9 and NGAL in human breast cancer 
 
The expressions of MMP-9 and NGAL in breast cancer have been thoroughly studied in 
human medicine these past years as the role of the two proteins in the tumoral progression 
soon became undeniable. 
 
• NGAL can protect MMP-9 from degradation  and increase tumoral growth rate 
After it was shown that the binding of NGAL to MMP-9 protected the extracellular matrix 
remodeling enzyme from degradation, Fernàndez and coworkers hypothesized that the 
addition of NGAL to MMP-9 expressing breast cancer cells might result in a more aggressive 
type of tumor after implantation in immunodeficient mice. Human breast cancer cells were 
transfected with human NGAL expression constructs and were implanted in mice in order to 
monitor the growth and aggressiveness of the tumor. Provoked NGAL expression increased 
significantly the growth rate of tumors as well as the expression of MMP-9, the angiogenesis 
and the tumor-cells proliferation. This study also showed by gelatin zymography that the 
NGAL/MMP-9 complex was detected in the urine of 86.36% of the tumor-implanted mice 
and none in the healthy controls (Fernàndez et al., 2005). This last result confirmed the 
findings of Shen et al who demonstrated on a sample of 97 breast cancer patients that MMP-9 
and NGAL expressions were valuable early prognostic factors in breast cancer (Shen et al., 
2003). 
 
• Serum concentrations of NGAL and MMP-9 can be markers of breast cancer status 
 
Provatopoulou and co-workers focused their work on the evaluation of serum concentrations 
of MMP-9, NGAL, and the complex form in 113 women with breast abnormalities 
undergoing breast biopsy and 30 healthy women to serve as negative controls. They showed 
by immunoenzymatic assays that both the expressions of NGAL and MMP-9 as well as the 
NGAL/MMP-9 complex were significantly increased in patients suffering from invasive 
carcinoma compared to the healthy patients. The serum concentration level of MMP-9 and 
NGAL were also significantly correlated with the disease severity score, but not of the 
complex form. Their work thereby suggested that MMP-9 and NGAL could be used as 
biomarkers of breast cancer status and that the serum measurement of the two proteins by 
immunoenzymatic assays could be a non-invasive method to monitor the progression of 
breast cancer (Provatopoulou et al., 2009). These results were emphasized in 2011 when Sung 
and co-workers demonstrated that elevated serum concentrations of both MMP-9 and NGAL 
were associated with reduced disease-free survival in 303 breast cancer patients (Sung et al., 
2011). 
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• MMP-9 is strongly expressed by the tumor cells 
 
The immunohistochemical staining with an anti-MMP-9 antibody of breast tumor cells also 
showed significant results. It was demonstrated that for 84.8% of 138 patients suffering from 
breast carcinoma, the tumor cells were positive in semi-quantitative evaluation of the MMP-9 
expression. Co-expression of MMP2/MMP-9 was a risk factor for patient survival but the 
relation between MMP-9 alone and survival rate was not significant. MMP-9 expression was 
also significantly correlated with other biomarkers frequently used such as estrogen and 
progesterone receptors (Ranogajec et al., 2012). 
 
This work confirmed the first results obtained by Monteagudo and co-workers concerning 
MMP-9. They performed immunohistochemical assays on normal, benign and malignant 
breast tissues and demonstrated that epithelial cells exhibited strong immunoreactivity in 20 
of 23 intraductal carcinoma cases. Invasive carcinomas were positive in 36 of 40 cases and 
metastatic cells in lymph nodes were stained in 10 or 12 cases. These results supported the 
role of the enzyme in tumor invasion and metastasis and suggested that tumor cells were the 
essential source of the enzyme in these processes (Monteagudo et al., 1990).  
 
• NGAL expression in breast carcinoma tissue is a predictor of poor prognosis 
 
Bauer and co-workers detected NGAL expression in 68 breast carcinomas in a cytoplasmic 
location. NGAL expression showed a significant correlation with poor histologic grade, 
presence of lymph node metastases and a high Ki-67 proliferation index. Its expression was 
also associated with decreased disease-free survival. NGAL detection may thereby provide 
information for risk assessment and may be useful to identify patients that may require a 
stronger adjuvant therapy (Bauer et al., 2008). 
 
 
3.2. MMP-9 in canine mammary gland tumors 
 
Because of the interest lifted by MMP-9 in human breast cancer articles, and because the 
human and canine mammary gland tissue share many similarities, few studies have been 
performed on canine MMP-9 to see if the results found in humans could be extrapolated to the 
canine mammary gland tumor. 
 
Zymography assays first revealed that the intensity of MMP-9 activity in the mammary 
carcinoma tissue was significantly higher than in the benign tissues. The metalloproteinase 
activity in carcinomas was more than 10-fold higher that in the controls. The MMP-9 
concentrations found in the sera of dogs suffering from mammary carcinoma were also higher 
than in healthy controls (Yokota et al., 2001). Similar results were obtained by Hirayama and 
co-workers (2002) and Kawai et al. (2006). 
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The same institute (Department of Veterinary Pathology at Rakuno Gakuen University) then 
studied the MMP-9 expression level in tumoral canine mammary tissue by 
immunohistochemistry with an anti human-MMP-9 antibody. It was shown that the 
expression of the metalloproteinase was very strong in epithelial cells of malignant tumors, 
and remained weak or moderate in benign tumors (Hirayama et al., 2002). 
 
Very recently, Santos and co-workers immunohistochemically evaluated MMP-9 expression 
in benign and malignant mammary tumors (MMT) in the aim to relate the expression to 
prognostic factors and patient outcome. By studying the staining of 118 different mammary 
tumor tissues, they showed that the MMP-9 expression was correlated with malignancy status, 
high proliferation, invasive growth, high histological grade and metastatic capacity. The 
assays were here again performed with an anti human-MMP-9 antibody (Santos et al., 2012). 
Their study was published few weeks after the beginning of this study. 
 
 
3.3. NGAL in veterinary medicine 
 
To our knowledge, no article concerning canine NGAL studies has yet been published and 
this is the first study on canine NGAL and its relationship with mammary gland tumors. 
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1. MATERIAL AND METHOD 
 
 




The canine MMP-9 antibody production was a major part of this study. The report of its 
production requires the insertion of several intermediate results, essential to link one step to 
the next, thereby resulting in a substantial material and method section. 
 
 
1.1.1. RNA extraction and reverse transcription 
 
• Total RNA extraction 
 
Tissue sample (0.2 g) was extracted from canine testicule with a surgical blade and the cells 
were lysed using liquid nitrogen, a mortar and a pestle. Total cell RNA was extracted using 
Qiagen®’s RNeasy® kit. The kit relies on using a spin-down column with a positively 
charged silica-based membrane that will retain the negatively charged RNA while letting cell 
debris, proteins and other unwanted components flow through.  Firstly the sample was lysed 
and homogenized in a highly denaturing buffer (RLT buffer) which inactivates RNase 
enzymes. A high-salt buffer system and the presence of ethanol to enrich binding conditions 
then allowed total RNA longer than 200 bases to bind to the membrane. Contaminants were 
washed away during the centrifugation and the total RNA (50 µl) was then eluted with 
Elution Buffer (Protocol 1 in Appendix 1). 
 
• Reverse transcription (RT) 
 
The total RNA was transcribed into cDNA using biological reverse transcription. 
(Invitrogen™’s Superscript™ III Supermix kit for qRT-PCR). The kit contains RT Reaction 
mix (contains the buffer, poly dT primers, random primers and 0.1M DTT) and RT Enzyme 
mix (contains reverse transcriptase and RNase inhibitors). The reverse transcription is 
performed by mixing the RT Reaction mix and Enzyme mix with the RNA sample and DEPC 
treated water and running the PCR machine for 1 cycle (Protocol 2 in Appendix 1). 
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1.1.2. Production of a cDNA insert 
 
• MMP-9 Hydrophobicity analysis and choice of the primers 
 
The aim was to produce 3 different MMP-9 antigens: one which would be the full length 
protein and two others which would only be a portion of the molecule, thereby inducing the 
formation of more specific antibodies. As the purpose of the antibodies produced from those 
antigens was to detect native form protein, the aim was to reproduce very hydrophilic portions 
of the protein, as such regions have high chances to be protruding in the environment rather 
than hydrophobic regions which have high chances to be inaccessible in the native protein. 
 
The expected hydrophobicity of canine MMP-9 was analysed using Kyte J and Doolittle R’s 
method (Kyte et al., 1982) and the proximal part as well as the distal part of MMP-9 showed a 
lower hydrophobicity than the rest of the molecule. It was decided to also produce two partial 
antigens: one would be the first quarter of the protein and the second one, the last quarter, 
each of them being around 170-200 amino acids (figure 6). 
 
 
• Polymerase Chain Reaction (PCR) 
 
Four different primers were thus ordered: 
 MMP-9-1F-35:  5’-AACATATGCAGCCCCTGGTCCTGGTGTTC-3’ (29 
nucleotides) 
 MMP-9-1R-544:  5’-AACTCGAGAACACCAAACTGAATGATGATG-3’ (30 
nucleotides) 
 MMP-9-1F-1580:  5’-AACATATGGCCATCGCGGAGATCAGGAACTAC-3’ (32 
nucleotides) 
 MMP-9-1R-2131:  5’-AACTCGAGGCACTGCAAAATGTCAAAG-3’ (27 
nucleotides) 
 
With the 4 primers ordered, 3 different PCR reactions were attempted (Appendix 2): 
- MMP-9-1F-35 and MMP-9-1R-544 (expected length: 500bp): obtained fragment 
should be the proximal part of MMP-9, which will be referred to as MMP-9-Prox. 
- MMP-9-1F-35 and MMP-9-1R-2131 (expected length: 2100bp): obtained fragment 
should be the full MMP-9 molecule, which will be referred to as MMP-9-Full 
- MMP-9-1F-1580 and MMP-9-1R-2131 (expected length: 550bp): obtained fragment 
is the distal part of MMP-9, which will be referred to as MMP-9-Dist (figure 7). 
  
 Figure 6: Hydrophobocity analysis of canine MMP
The regions showing the lowest hydrop
MMP-9-Prox and MMP-9-Dist are labeled and 
 
The template DNA was mixed with the forward primer, the reverse primer, nucleotides, 
polymerase and 35 PCR cycles were performed (Protocol 3
electrophoresis (Protocol 4 in Appendix 1) was used to check the PCR products (
 
Figure 7: Agarose gel electrophoresis to verify the size of the 
The three reactions MMP-9-Prox, MMP
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The fragments obtained from reactions 1 (MMP-9-Prox) and 2 (MMP-9-Dist) were 
compatible with the expected size. However, the amplification of the region coding for the 
full length MMP-9 seemed to have failed as the obtained fragment was 1500bp, compared to 
the 2100bp expected. This reaction was repeated several times but it always failed to give us a 
fragment of the right size. The project to create a full length antigen was stopped here. 
 
1.1.3. Introduction to Novagen’s pET-24a(+) vector 
 
The vector used in this project was Novagen’s pET-24a(+) (Appendix 3). This plasmid has a 
kanamycin resistant gene that was used in later steps as a selection marker and also offered 
the possibility of adding a histidine-tag at one end of the antigen. The histidine-tag is an 
alignment of 6 histidine residues that can be added at the C- or the N-terminus of the protein. 
It is poorly immunogenic, and at pH 8.0, it is small and uncharged, thus not affecting the 
antigenic properties of the protein. This tag gives the protein a very high affinity for Ni-NTA 
(nickel charged iminodiacetic acid) therefore offering the possibility to use this specific 
binding as a purification method once the protein has been expressed. Another interesting 
advantage is that it makes the protein easily detectable by anti-histidine-tag antibodies. 
 
In this study a pET-24(a) plasmid that already contained a 1700bp insert was used.  
  
1.1.4. Digestion of the vector, digestion of the insert and ligation 
 
• Digestion of pET-24a vector 
 
In order to ligate the insert inside the vector, both of them needed to be digested with the same 
restriction enzymes, namely Nde I and Xho I (figure 8). These two enzymes were chosen 
because both have a unique cutting site in the vector’s sequence, none of them has a cutting 




Figure 8: Map of pET-24a(+) expression region 
The enzyme restriction sites used (Nde I and Xho I) are shown in red. The histine-tag, which will be used in the 
purification of the protein is marked in green. 
 
 The choice of the enzymes was made before ordering the primers. It allowed to input a cutting 
site inside the primer, thereby giving 
extremities. 
 
To perform the digestion, the plasmid DNA was added in an Eppendorf tube containing 
ddH2O (double distilled water)
(Protocol 5 in Appendix 1). 
electrophoresis. Because the 
expected: the first one around 5000bp, corresponding to the digested plasmid, and the second 
one at 1700bp, which matched 
both components could be detect
 
Figure 9: Products of pET
 
The 5000bp mark was then cut from the gel and eluted by using Geneaid™’s Gel DNA 
Fragments Extraction Kit. This ensures us to farm only 
the old 1500bp insert (Protocol 
 
• Digestion of the cDNA insert
 
The cDNA inserts of MMP-9
using the same protocol as the one used for the vector (Protocol 
• Ligation 
The ligation is the operation in which the DNA of 
vector (figure 10). The proportions of plasmid and insert to use in the reaction 
determined by the signal intensity of those two components on a 1% agaros
electrophoresis. The aim was to have 2
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The solution (4 µl) was then checked on a 1% agarose gel 
plasmid already contained a 1700bp insert, two marks
with the excised insert. The digestion was judged successful as 
ed (figure 9). 
 
-24a digestion by NdeI and XhoI on 1% agarose gel 
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the competitivity of the desired reaction and to minimize the risk of obtaining self-ligation 
(i.e. plasmid closing back on itself without integrating the DNA insert). The ligation is 
performed by mixing the DNA insert with the plasmid and DNA ligase enzyme and leaving 
the mixture at 4°C overnight (Protocol 7 in Appendix 1). 
The ligation could also be carried out at 16°C or even 37°C but the low temperature, though 
making the reaction slower, increases its specificity and minimizes unwanted reactions such 








The pET-24a-MMP-9 plasmid was then inserted inside competent E.coli cells. The bacteria 
used in this study were One Shot® Top10 competent E.coli from Invitrogen®. These bacteria 
have very high transformation efficiency and are ideal for high-efficiency plasmid cloning as 
they allow stable replication of plasmids in a high-copy number. It is important to mention 
that these bacteria contain no plasmid, which means that the only one that will be present after 
the transformation were pet24a-MMP-9. However, this also means that the Top10 E.coli do 
not have the necessary cellular equipment to express the protein. They were used to clone the 
plasmid prior to transforming them in another type of bacteria (BL21) that contains other 
plasmids as well as all the cellular machinery needed to produce the antigen. 
  
• Preparation of the competent cells 
 
The first step consisted in preparing the competent cells by refreshing an overnight culture 
and incubating it until it has reached the logarithmic phase of its growth curve. 
This moment was determined by spectrophotometry at 600nm. By using a clean LB-broth 
sample as standard, the log phase starts when the sample’s optical (OD) was between 0.3 and 
1. When the OD reached 0.4, the growth was stopped. The bacteria pellets were centrifuged 
and cleaned with 0.1M CaCl2 washes. CaCl2 was used to positively charge the bacteria, thus 
increasing its attraction to the negatively charged DNA plasmid, and increasing the chances of 
successful transformation. Glycerol was also added to enable the stocking at -80°C (Protocol 
8 in Appendix 1). 
 




The aim of the transformation step was to mix the negatively charged plasmid DNA with the 
positively charged competent cells and to use a heat shock to make the cells permeable 
enough to acquire the plasmid. At first the two different components were mixed and left on 
ice, in order for the plasmid and the cells to get closer to one another as they are attracted by 
their opposite charges. The mixture was then quickly bathed at 42°C. The sudden increase of 
temperature was used to enlarge the pores of cell membrane and increases the cell 
permeability, therefore allowing the pET-24a-MMP-9 plasmid to enter the cell during this 
short period of time. The sample was then quickly thawed on ice, in order to close the 
bacteria’s pores and to trap the plasmid inside the cell (Protocol 9 in Appendix 1). 
 
• Colony selection 
 
LB broth free of any antibiotic was then added into the tube and the sample was incubated for 
a short period of time in order to allow the bacteria to start their growth. A small volume of 
the bacteria culture was streaked onto a LB agar plate containing kanamycin. Top10 E.coli are 
naturally sensible to kanamycin and only those that have captured the plasmid containing a 
kanamycin resistance gene should be able to grow. The culture plate is incubated at 37°C for 
18 hours and the resistant colonies were selected (Protocol 10 in Appendix 1). 
 
The kanamycin plate allowed to keep only bacteria that have gone through a successful 
transformation. This means that any bacteria which managed to develop on the plate must 
have received a pET-24a(+) plasmid, but it was of no guarantee that the plasmid it had gotten 
contained the MMP-9 DNA insert, as it could be a self-ligated plasmid. After this colony 
selection a colony screening has to be performed. 
 
 
1.1.6. Colony screening 
 
Three different methods (PCR screening, analysis of enzyme digestion pattern, and 
sequencing) were used in order to verify that the selected colonies had a pET-24a(+) plasmid 
containing the MMP-9 DNA sequence insert. Those methods were  
 
• PCR screening 
 
For both MMP-9-Prox and MMP-9-Dist, 20 colonies were selected from the kanamycin plates 
and were amplified using the corresponding primers. 
 
Single colonies were picked from the LB plate and resuspended in 30 µl of ddH2O. Sample 
fractions (2 µl) were tested by PCR and the remaining fraction (28 µl) would be used for 
bacterial inoculation if the colony was proven to be positive. The screening by PCR was 
performed by mixing the resuspended bacteria with the forward and reverse primers used in 
Protocol 3 as well as with DNA polymerase enzyme and nucleotides. 
  
The sizes of the PCR products 
(figure 11). The colonies showing the strongest 
next screening test. 
 
Figure 11: PCR products obtained for 20 colonies after transformation with pET
carrying MMP
Most of the colonies selected showed a successful tra
matching with the size of the MMP
 
 
• Enzyme digestion pattern
 
After the overnight incubation of the L
was selected and was grown 
developed and cloned the plasmid they ha
using a Geneaid® High Speed Plasmid Mini Kit
alkaline lysis and RNase treatment to obtain clear cell lysate with minimal genomic DNA and 
RNA contaminants. The plasmid DNA in the lysate binds to the glass fiber matrix of the 
Column that is provided in the kit. Contaminants 
containing ethanol and the purified plasmid DNA eluted 
(Protocol 11 in Appendix 1). 
 
After elution, the plasmid DNA
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figure 12). 
 Figure 12: Enzyme digestion profile of the plasmids extracted from colonies after 
transformation with pET





Finally, a LB plate containing isolated colonies 
laboratory in Taipei to sequenc
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1.1.7. Transfer of the
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1.1.8. Large scale expression and protein extraction 
 
• Antigen expression 
 
A single colony was picked from the LB plate and incubated in a 10 ml kanamycin enriched 
LB broth culture at 37°C overnight. The culture was then refreshed at a 1/20 ratio into a new 
medium and incubated at 37°C for about 2 hours, until the optical density reached 0.6 at 
595nm. A fraction (1 ml) was sampled from the culture, and was stored at -20°C as the “no 
induction” control. The rest of the culture was induced with 0.8 mM IPTG. 
 
Though MMP-9-Prox could be produced in small scale expression tests (Protocol 12 in 
Appendix 1), it seemed impossible to produce it in large scale. Many different conditions 
have been attempted, such as different IPTG concentration (0.2-2 mM), expression 
temperature (25-37°C), expression time (2-24 hours), but all of them resulted in a production 
extremely low if not completely absent. After several repeats, the project to create 
recombinant MMP-9-Prox was aborted. 
 
For MMP-9-Dist, several different expression conditions have been experimented and the 
optimal expression protocol was an incubation at 25°C for 24 hours (Protocol 13 in Appendix 
1). 
 
• Antigen extraction 
 
The aim of the next steps was to lyse the bacteria in order to free the protein. For that, freeze 
(-80°C) and thaw (37°C) cycles were used in order to inflict to the bacteria an important heat 
shock. To make sure the bacteria were lysed, lysozyme was added and the sample was put in a 
37°C waterbath. Sonication with ultrasounds was then performed. The sample was 
centrifuged and the supernatant and pellet were separated. 
 
The native protein is soluble; therefore it was dissolved in the supernatant. However, the 
denatured form, which in this case represented the majority of the protein, was still trapped in 
the pellet. To make it soluble, the pellet was resuspended with a new buffer, containing a high 
concentration of urea (8M) and salt (1M) and repeated the steps of sonication and 
centrifugation (Protocol 14 in Appendix 1). 
The fact that the protein should have six histidine residues (his-tag) at the C terminal end was 
used to purify the antigen. 
 
Some amino-acids, such as histidine, can form complexes with metal ions, in particular the 
nickel ion Ni2+. If this ion is immobilized on a chromatographic medium by chelating to a 
suitable ligand, the amino-acids can bind to the medium and the proteins showing great 
proportions of them can be retained while the other proteins can be washed off. This is the 
principle of immobilized metal ion affinity chromatography (IMAC). 
GE Healthcare’s Chelating Sepharose™ contains iminodiacetic acid groups coupled to 
sepharose. After being charged by nickel, it can bind very efficiently to sequences alignement 
 that have multiple histidine residues next to each other. Therefore its binding to 
Dist should be much more important than its binding to the bacteria endogenous proteins. 
This binding can be neutralized by adding an imidazole enriched buffer
binding depends on the affinity between the beads and the proteins, and the stronger this 
affinity is, the higher the required imidazole concentration 
Therefore the first washes were
unbind all the proteins that are not highly bound to the sepharose. 
histidine-tag were highly bound
concentrations. The protein content of the flow
dye. When this test revealed that the flow
elements that were unspecifically bound to the sepharose ha
elution process was started. 
 
The only difference between the washing buffer and the elution buffer 
in imidazole. This time, instead of being 2
elutions and 400 mM for the last one. Here again, the protein content 
protein dye and when it was very low, 
last steps of the protocol was to wash the column of sepharose with a regenerating buffer that 
contains EDTA (Protocol 15 in Appendix 1
 
Finally, a SDS-PAGE (Protocol 
of the protein in the different samples (
 
MMP-9-Dist was the major protein in the eluted samples but a lot of contaminants were also 
visible. Further techniques were thereby applied to increase the purity of the antigen.
 
Figure 13: Verification of the histidine
an expression done at 25°C for 24 hours
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1.1.9. Protein purification 
 
• Extraction of the protein from PVDF membrane 
 
The proteins of the different elution samples were then separated by SDS-PAGE and 
transferred on a PVDF membrane. The membrane was then stained with Ponceau S and when 
the proteins became visible, MMP-9-Dist was located and cut. The piece of membrane was 
destained in ddH2O for a few minutes and inserted in a new microcentrifuge tube containing 
an Elution Buffer. It was vortexed during 10 minutes and the membrane pieces were 
discarded. The elution efficiency was evaluated by checking with Ponceau S that the 
membrane pieces did not contain anymore protein (Protocol 17 in Appendix 1). 
 
• Acetone precipitation 
 
As the Elution Buffer used to elute the antigen from the membrane contained 2% SDS, it was 
not possible to use the sample for immunization before cleaning out all the SDS away. 
Regular dialysis was first thought to be the good option but it showed to be unsuccessful as 
the sample seemed to still contain a lot of SDS. Acetone precipitation was thereby chosen. 
 
After adding a 4:1 volume ration of cold acetone the proteins precipitated. Afterwards 
centrifugation was performed to discard the supernatant that contained the Elution Buffer. The 
pellet was then resuspended in PBS. Therefore this technique also helped to concentrate the 
antigen by adding a small buffer volume to resuspend the pellet (Protocol 18 in Appendix 1). 
 
 
1.1.10. Antigen concentration estimation 
 
In order to estimate the protein concentration, a SDS-page was performed with the different 
samples and bovine serum albumin (BSA) standards of known concentrations (1000 µg/ml, 
500 µg/ml, 250 µg/ml and 100 µg/ml). The gel was then stained and pictured and the signal 
intensity of the antigen was compared to the one of the standards using Image J computer 
software, and the concentrations were determined (Appendix 4). 
 
The purity of the antigenic solution was also estimated by comparing the MMP-9-Dist 
concentration with the concentration of contaminants, eventually present in the sample. Any 
sample showing a purity rate lower than 50% was discarded or re-purified. If no other protein 
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1.1.11. Immunization and antibody retrieval 
 
Prior to immunize, it was verified by Western Blot (Protocol 19 in Appendix 1) if the antigen 
was indeed the recombinant MMP-9-Dist. Using an anti-histidine antibody as the primary 
antibody, it was shown that the tested samples were very rich in a 22kDa protein that showed 
strongly positive for the histidine-tag (figure 14). 
 
 
Figure 14: Western Blot result to verify the presence of the histidine-tag on the purified 
protein 
 
The antigen was mixed with the adjuvant (Freund’s adjuvant complete sigma) in a 1:1 volume 
ratio prior to being injected via intraperitoneous injection in three mice. One prime-injection 
and three boosting injections were performed for each mouse (Appendix 5). 
Before each antigen injection, a blood sample was taken from the orbital sinus of each mouse. 
Blood was centrifuged at 6,000 g for 5 minutes; the serum was retrieved and stored at -20°C. 
The final serum was retrieved one week after the third boost and was used as a polyclonal 
antibody against canine MMP-9. 
 
1.2. Production and purification of anti canine NGAL antibody 
 
1.2.1. Recombinant NGAL production 
 
The recombinant NGAL used to induce the production of antibodies was not produced during 
this study. This project only included the retrieval of the serum and the purification of the 
antibodies.  
Mammary gland tissue was homogenized and total RNA was extracted. cDNA was 
synthesized using reverse transcription and the open reading frame of NGAL was amplified 
by PCR. The primers were designed according to GenBanl accession no. XM 548441.The 
gene was then cloned into a pET-32b vector and expressed in E.coli. strain BL21® 
(Invitrogen™) at 16°C for 24 hours after IPTG induction. 
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After centrifugation of the culture, the bacteria pellet was resuspended in lysis buffer 
containing a high concentration of urea and was subject to sonication. After a second 
centrifugation, the supernatant was mixed with the Nickel charged sepharose and incubated at 
4°C for 2 hours. The sepharose was then washed several times and finally the bound protein 
was eluted and dialyzed against PBS at 4°C. The identity of the NGAL protein was confirmed 
by Western-Blot analysis using antibody against the histidine-tag and by mass spectrometry. 
 
Three BALB/c mice aged eight weeks and three month old New Zealand white rabbits were 
immunized. Two boosters were given at two-week interval. 
 
After the final bleeding, the sera were analyzed by Western-blotting. They were able to 
recognize the recombinant protein, whereas no signal was detected when the pre-
immunization sera were tested. The sera were then tested by Western-Blot on clinical urine 
specimens. A protein of 25kDa, the expected size of endogenous canine NGAL, was detected 
in renal failure dogs but not in healthy dogs. 
 
To use the antibodies for IHC, two purification methods were performed in order to enrich 
and concentrate the rabbit serum: ammonium sulfate precipitation and purification by protein 
G. 
 
1.2.2. Antibody purification by ammonium sulfate precipitation 
 
As the concentration of ammonium sulfate is increased in a sample, proteins become 
progressively less soluble until they precipitate. Antibodies precipitate at lower concentration 
of ammonium sulfate than most other proteins and serum macromolecules. At 40 to 50% 
ammonium sulfate saturation (100% saturation equaling to 4.32M), immunoglobulins 
precipitate while other serum proteins and components remain in solution (Protocol 20 in 
Appendix 1). 
 
Ammonium sulfate precipitation provides sufficient purification for some applications but 
most often it is performed as a preliminary step prior another purification technique. The 
second technique used was column chromatography with Protein G. 
 
 
1.2.3. Antibody purification by Protein G 
 
This method relies on the fact that the protein G sepharose has a strong affinity for the Fc 
region of immunoglobulins. This property enables the G beads to trap the IgG and by running 
the rabbit serum on a column containing 2 ml of Protein G sepharose beads, it allowed to 
wash off the contaminants. The binding of the IgG was then cancelled by using a 100 mM 
glycine solution at pH3.0 and the antibodies were eluted (Protocol 21 in Appendix 1). 
 













Figure 15: SDS-PAGE verification of the elutions retrieved after Protein G sepharose 
The flow-throughs are labeled FT1 and FT2, the wash
E1-E4 for fractions 1-4. Note that the heavy chain of th












-through is labeled W and the elution fractions are labeled 
e antibodies, at around 55kDa, was the major component 
 The protein size ladder is labeled M.
 
 




The aim of the NGAL sandwich ELISA was to evaluate the expression of NGAL in the urine 
and the serum of female dogs suffering from malignant mammary gland tumor
compare it with the basal expression found in healthy dogs.
 
A total of 28 blood serum samples 
dogs.  All patients suffered from at least a simple carcinoma or a complex carcinoma or both 





Prior to start, serial dilutions of the recombinant canine NGAL 
5.6 µg/ml to 0.22 ng/ml).  
To establish sandwich ELISA test, two antigen specific antibodies raised from different 
animal species, are required
originating from mice which will be the detecting antibody and the second one from rabbit 
which will serve as the capture antibody
 
The principle was to make a coating with the rabbit antibody prior to apply the clinical 
samples. The capture mouse antibody was then applied and an  enzyme
antibody that binds specifically to the mouse anti
TMB as enzyme substrate of the enzyme conjugated 
to obtain a color signal (figure 1
 
Figure 16: Schematic view of the NGAL sandwich ELISA principle
(1) Plate is coated with  rabbit capture antibody; (2) sample is added, and any antigen present binds to capture 
antibody; (3) mouse detecting antibody is added, and binds to antigen; (4) enzyme
added, and binds to mouse antibody; (5) substrate is added, and is converted by enzyme to detectable color form.




and 8 urine samples were obtained from female 
  
were used
: two home-made canine NGAL antibodies, the first on
, were used in this study. 
-conjugated secondary 
body Fc region was then added. Finally, 
to the secondary antibody 
6).  
 
-linked secondary antibody is 
s, and to 
diseased 
 as standards (from 
e 




- 59 - 
 
1.3.3.  Optimized protocol 
 
• Capture antibody coating 
 
Rabbit anti-NGAL antibody diluted at a 1:800 rate in ELISA Coating Buffer was used as the 
capture antibody. All wells of the ELISA plate were filled with 100 µl and incubation was 




150 µl of ELISA Blocking Buffer was added in each well and left 1 hour at room temperature 
before being washed off. 
 
• Antigen addition 
NGAL standards 1-8 and standard PBS were added in triplicates. For each clinical sample, 20 
µl of the sample was diluted in 380 µl of PBS and three wells were filled with 100 µl of the 
mixture, prior to overnight incubation at 4°C. The wells were then washed 5 times with PBS. 
 
• Detecting antibody 
Mouse anti-NGAL antibody diluted at a 1:3000 dilution rate in 5% skim milk was used as 
detecting antibody. 100 µl of the mixture was added in the wells prior to incubation at 37°C 
for 1 hour. The wells were then washed 5 times with PBS. 
 
• Enzyme-linked secundary antibody 
Goat anti-mouse-Fc antibody was diluted at a 1:5000 rate in 100 µl of 5% skim milk and 
added in each well. The plate was then incubated for 1 hour at 37°C and the wells were then 
washed 10 times with PBS. 
 
• Substrate addition 
 
100 µl of TMB was added in each well and the plate was left 5 minutes in a dark room. The 
reaction was then neutralized with 50 µl of H2SO4 (2M). 
 
• Revelation 
The optical density of each well was then analyzed by spectrophotometry (wave length: 420-
620nm). 
 
The assays were repeated twice for each sample and the average OD was determined as final 
result. For more details concerning the optimized protocol, see Protocol 22 in Appendix 1. 
  




1.4.1. Nature and origin of the samples 
 
Samples were obtained by excisional biopsy from 43 female dogs admitted to Chung-Hsing 
University’s veterinary medicine teaching hospital for clinical evaluation and treatment of 
mammary tumors during the years 2010 and 2011. None of these dogs had undergone any 
chemotherapy or radiotherapy prior to the mastectomy or nodulectomy. All patient data was 
recorded (final diagnosis, histological grade, lymph node metastase status and several more 
informations). The histological diagnosis was established by pathologists after hematoxylin 
and eosin staining and histological classification as well as malignancy grading followed the 
WHO classification of canine mammary tumor (Misdorp et al., 1976). For each dog, the slides 
containing tissue representing the major diagnosis were kept for IHC. 
 
In total, 43 samples have been tested. 32 were malignant tumors (20 complex carcinoma, 11 
simple carcinoma, 1 carcinosarcoma) and 11 were benign (8 benign mixed tumors, 2 complex 
adenoma, 1 simple adenoma). 
 
IHC was performed on 4 µm sections of formalin-fixed, paraffin embedded tissue samples. 
 
To compare the expression of MMP-9 and NGAL in healthy and cancerous mammary tissues, 
IHC assays were also performed on 13 healthy samples. These samples were obtained from 
non cancerous mammary glands according to histological diagnosis that had been excised at 
the same time as the tumor, when a full mastectomy was performed. 
 
 
1.4.2. Immunohistochemistry protocol for NGAL 
 
The IHC protocols and the reagent conditions greatly differ and depend on the tissue type, the 
target protein, the antibody, the reagents used...  Prior to start the staining of the samples, 
different assays were tested in order to determine the optimal conditions for specificity, 
background and resolution of the signal.  
 
The following protocol (Protocol 23 in Appendix 1) describes the conditions that were judged 
to be optimal. More information concerning the conditions that have been tested can be found 
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• Deparaffinization and rehydration  
 
The slides were first deparaffinated in two successive pre-heated (50°C) xylene solution bath, 
each one lasting 15 minutes in a 50°C incubator. They were then gradually rehydrated by first 
soaking them in two successive 100% ethanol bath (two times three minutes), one 95% 
ethanol bath (three minutes), one 75% ethanol bath (three minutes) and finally one 50% 
ethanol bath (three minutes). 
 
• Antigen retrieval 
 
The reagents used in tissue fixation can form protein cross-links that mask the antigenic sites 
of the sample, thereby giving false negative staining or lowering drastically its strength. 
Therefore a citrate based solution that can break the protein cross-links and unmask the 
epitopes in formalin-fixed and paraffin embedded tissue samples was used. 
For that, the slides were soaked in a plastic container with 1L of Citrate Buffer and were 
heated at 800 watts for 20 minutes. The level of the buffer was regularly checked to make 
sure it was not excessively lowered because of evaporation.  
The plastic container is then cooled down in a room-temperature water-bath for ten minutes. 
• Circling 
 
The slides were shaken dry, the non interesting tissue portions were discarded using a cotton 
swab, and the tissue section is circled with the Dakopen. This circle allows to use smaller 
quantities of reagents and antibodies in the next steps and helps preventing the tissue from 




Background or unspecific staining often occurs if the blocking step is omitted.  
- Inhibition of endogenous peroxydase: endogenous peroxydase in the tissue can also 
degrade the substrate used in the revealing step, thereby giving an unspecific staining. 
A 3% hydrogen peroxyde solution was applied on the tissue sections for 10 minutes 
followed by three ddH2O washes. 
 
- Blocking of the unspecific binding of the primary antibody: the primary antibody can 
also bind unspecifically, therefore giving a false positive signal. A 5% Goat Serum 
solution was applied on the slides for 30 minutes followed by three ddH2O washes. 
 
• Primary antibody 
The primary antibody was diluted at a 1:400 dilution rate with Dako REAL™ antibody 
diluant and approximately 300 µl is applied on the tissue sections for two hours. During that 
time, the IHC box is closed with a lid to avoid tissue dehydrating. Slides were then washed 
five times with ddH2O. 
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• Secundary antibody 
 
As Dako REAL™ EnVision™ HRP Rabbit/Mouse secondary antibody can detect both mouse 
and rabbit antibodies, it was thereby used for both NGAL and MMP-9 IHC. It was applied on 




To reveal the peroxydase action of the secondary antibody’s peroxydase, Dako REAL™ DAB 
(3,3’-diaminobenzidine) diluted to 1:250 in Dako REAL™ Substrate buffer was applied for 




Tissue sections were counterstained with hematoxylin for thirty seconds. The slides were then 
washed with ddH2O and soaked in tap water for one minute. The alkaline status of the tap 
water makes the hematoxylin form an insoluble blue aluminium haematin complex that colors 
the nucleus in blue. 
 
• Dehydration and mounting 
 
The slides were dried in a 50°C incubator overnight and were mounted the next morning. 
They were dried at room temperature for two hours before being read. 
 
 
1.4.3. Immunohistochemistry protocol for MMP-9 
 
The IHC protocol for MMP-9 was very similar to the one used for NGAL. The only 
difference remained in the dilution of the primary antibody (1:100 instead of 1:400) and in the 
duration time of the DAB (3 minutes instead of 2 minutes 15 seconds). 
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1.4.4. Positive and negative controls 
 
• Positive controls 
 
For each batch of IHC staining, one slide known to be positive was included. These slides 
served as quality control for the whole batch. If it was judged to be of lesser quality than 
usual, all the slides of the corresponding batch would be discarded. 
 
• Negative controls 
 
In order to prove that the positive signal of the sample slides is specific, a negative control for 




1.4.5. Reading and scoring 
 
Each slide stained using the optimized IHC protocol was analyzed with following parameters:  
- Existence and specificity of the staining  
- Cellular distribution of the staining 
- Homogeneity of the staining throughout the tumor section 
 
Additionally, the expression of the protein was determined semi-quantitatively by scoring: 
- The intensity score (IS) of the staining (by comparison with the standard slide, judged 
as highly stained) 
o no staining: score 0 
o low : score 1 
o medium: score 2 
o high: score 3 
- The proportion score (PS) of positive tumor cells 
o Less than 10%: score 1 
o 11-50%: score 2 
o 51-80%: score 3 
o More than 80%: score 4 
 
The final score (FS) of a slide was the product of those two scores. A FS between 0-2 is 
considered negative, a FS between 3-7 is considered weakly positive and a FS between 8-12 
is considered strongly positive. The score was evaluated by two different observers. If their 
opinions were different, the score would be discussed until an agreement was found (If no 
agreement could have been found, the slide would have been discarded from the study but this 
problem did not occur). 
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1.5. Statistical analysis 
 
T-tests (with or without Aspin-Welsh correction) for the ELISA results, Fisher exact tests for 
the ELISA and IHC results and Spearman’s correlation test to evaluate the correlation 
between MMP-9 and NGAL expression were all performed with GraphPad™ Prism software. 
All tests resulting in a p < 0.05 were considered significant. 
  





2.1. Anti canine MMP-9 antibody 
 
After the bleeding and the serum retrieval, the efficiency of the antibody was tested by 
Western-Blot on different samples. It was first verified that the mice serum could detect the 
recombinant MMP-9-Dist protein, prior to check its efficiency on commercial human MMP-9 
and finally on canine mammary gland tissue homogenates. 
 
2.1.1. Ability to detect the recombinant MMP-9-Dist 
 
As seen on figure 17, the anti-histidine tag antibody, used as a positive control shows a signal 
at 22kDa which is the size of MMP-9-Dist. The sera taken prior to 2nd and 3rd boost can also 
detect target protein and with a signal strength that increases as the boost number raises. The 
fact that the pre-immune serum does not detect any protein serves as a negative control. 
Another protein (around 40kDa) seems to be strongly detected by the serum; this is due to the 
fact that the purity rate of the MMP-9-Dist used for this test was around 95% and other 




Figure 17: Verification of the mouse-2’s serum immunized with recombinant MMP-9 by 
Western blot analysis 
 
Recombinant MMP-9-Dist was resolved with SDS-PAGE and analyzed by Western blotting with various 
antibodies including anti-histidine tag (H), mouse pre-immunized serum (P.I), and the serum taken prior to 
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2.1.2. Ability to detect human MMP-9 
 
As no commercial canine MMP-9 exists, capacity of the mouse serum to detect the 
commercial human MMP-9 (abcam™) was evaluated by western blot. 
 
In this case, a negative result would not be interpretable as the antibody could have been 
specific enough for the canine protein but not to the human one. In this study, the antibody 






Figure 18: Detection of human MMP-9 by the serum of mouse 2 
A: Commercial human MMP-9 was resolved with SDS-PAGE and processed for Western blot analysis with 
mouse 2 serum prior to the 3rd boost as primary antibody. 
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2.1.3. Ability to detect canine MMP-9 
 
 
As mentioned earlier, although no commercial canine MMP-9 protein exists, the antibody 
efficiency was directly tested on mammary gland tissue homogenate. Two different samples 
were tested: mammary gland carcinoma and mammary gland adenoma homogenates. 
 
A strong signal could be noticed at around 100kDa which corresponds to pro-MMP-9. The 
second signal, detected few kDa lower than pro-MMP-9 (approximately 90kDa) and of 




Figure 19: Verification of the antibody authenticity on mammary gland tumor tissue 
homogenates 
Mammary gland tumor carcinoma homogenate (C) and mammary gland tumor adenoma homogenate (A) were 
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2.1.4. Evaluation of relative titers antibody of mouse sera 
 
 
An ELISA assay was performed using the recombinant MMP-9-Dist as the antigen and the 
mouse immunized serum as primary antibody. Both pre-immune (PIS) and final sera (FS) of 
all three mice were tested. Each one was tested at different dilutions, from 1:100 to 1:3200 in 
order to determine the relative antibody titer of the different sera. The endpoint titer was 
determined by calculating a cut-off (equaling to two times the mean optical density of the 
negative control) and by determining the antibody dilution that would have been necessary to 
obtain a result equal to the cut-off. The end point titer was calculated with GraphPad Prism® 
software. 
 
The highest endpoint titer was obtained for mouse 2 at 1:5841 (table 1) that was then used for 




Table 1: Titration of the sera by ELISA (optical density) 
Dilution                 Mouse 1 
      PIS                  FS         
              Mouse 2 
      PIS                  FS         
              Mouse 3 
      PIS                  FS         
1:100 0.046 0.527 0.045 0.670 0.047 1.01 
1:200 0.048 0.453 0.045 0.475 0.044 0.486 
1:400 0.048 0.306 0.047 0.356 0.045 0.269 
1:800 0.041 0.208 0.043 0.266 0.045 0.187 
1:1600 0.041 0.132 0.049 0.228 0.045 0.115 
1:3200 0.044 0.075 0.042 0.1015 0.044 0.064 
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2.2. NGAL Sandwich ELISA  
 
2.2.1. Blood samples 
 
Because the standard curve, made by regression of the standard values, was not linear, and 
because the inter-assays variations were relatively high for standard samples as compared to 
the clinical samples, it was decided not to intrapolate the NGAL expression from the optical 
density (OD) values. The expression was thereby evaluated by comparing the different ODs 
observed for all the samples (table 2 and figure 20). 
 
The average and median ODs of the healthy sera were respectively 0.128 and 0.127, barely 
lower than the average (0.147) and median (0.164) values observed for MMT samples. 
 
Table 2: Optical density observed after NGAL sandwich ELISA performed on healthy 
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As the variances of these two sets of data were unequal, the Aspin-Welsh corrected T-test was 
performed on these values and obtained a p-value equal to 0.116, showing that there is no 






Figure 20: Repartition of the optical density values observed after NGAL sandwich 
ELISA performed on healthy and MMT serum samples 
 
A cut-off value was created by calculating the average of the healthy sample values added to 
two times the standard deviation of the values. The cut-off value resulted in 0.193, which 
gave the following contingency table (table 3). 
 
 
Table 3 : Serum NGAL expression contingency table after definition of the cut-off value 
(0,193) 
Optical density Healthy MMT 
< Cut-off (0.193) 14 19 
> Cut-off (0.193) 0 9 
P=0.0155  
Sensitivity=0.4242 / Specificity=1 
 
Fisher’s exact test applied to this contingency table shows a significant correlation between a 
serum NGAL concentration higher than the cut-off value and cancer disease status 
(p=0.0155), however the sensitivity of this test remains low (42%). 
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2.2.2. Urine samples 
 
The average and median urine concentrations of NGAL were higher in MMT (0.097 and 
0.086) than in healthy patients (0.048 and 0.048) (table 4 and figure 21); as the variances were 
unequal, the Aspin-Welsh corrected T-test was performed and a p-value equal to 0.0342 was 
obtained, suggesting that the difference is significant.  
 
 
Table 4: Optical density observed after NGAL sandwich ELISA performed on healthy 




















Figure 21: Repartition of the optical density values observed after NGAL sandwich 
ELISA performed on healthy and MMT urine samples 
Note that the extreme value of (0.752) was not added on the graph 
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A cut-off value was defined as equal to (average + 2*Sd) of the healthy samples values. The 
cut-off value was thereby 0.0541 and resulted in the contingency table presented as table 5. 
 
 
Table 5: Urinary NGAL expression contingency table after definition of the cut-off value 
(0,0541) 
Optical density Healthy MMT 
< Cut-off (0.0541) 5 2 
> Cut-off (0.0541) 0 6 
P=0.0163  
Sensitivity=1 / Specificity=0.75 
 
The correlation between NGAL concentration in urine higher than the cut-off and cancer 
disease status was significant (Fisher exact test, p=0.0163). The cut-off showed an excellent 
sensitivity and an average specificity (100% and 75%). 
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2.3. NGAL Immunohistochemistry results 
 
 
2.3.1. Efficiency of the staining 
 
All 43 tumor samples slides and all 13 healthy tissue slides were immunohistochemically 
stained using the protocol described in the material and method section. Most of the samples, 
even tissue sections originating from healthy mammary glands, showed at least a few luminal 
epithelial cells positive for NGAL and MMP-9, whereas the negative control performed with 




Figure 22: Comparison of tissue labeling with home-made anti MMP-9 antibody and 
pre-immune serum as a negative control 
 
Expression of NGAL and MMP-9 was demonstrated in all the tumor samples. Marked 
differences between staining were most often noted not in the proportion of positive cells but 
rather in the intensity of expression of the studied proteins (figure 23). For both proteins, the 
staining was almost exclusively in the cytoplasm of luminal epithelial cells, but some rare 
stromal cells sometimes showed positivity. 
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Figure 23: Intensity score graded between 0 (no staining) and 3 (strong staining) 
 
 
2.3.2. Correlation between cancer status and MMP-9 and NGAL 
expression 
 
Expression of NGAL (table 6) and MMP-9 (table 7) were determined semi-quantitatively in 
healthy tissues, tissues from benign tumors and tissues from malignant tumors. For MMP-9, 
most of healthy samples were negative (84.6%) and few were weakly positive (15.4%), 
whereas all tumor samples, either benign or malign, showed at least weakly positive (figure 
24). For NGAL, the majority of healthy glands (61.5%) were negative; however the 
proportion of healthy samples to be weakly positive was much higher (38.5%) than for MMP-
9 staining. For both proteins, no healthy control was noted as strongly positive. 
 
The Fisher exact test was used to analyze differences in expression of MMP-9 and NGAL 
between healthy samples and tumoral ones. By grouping the weakly and strongly positive 
results together, a significant correlation between the expression of both proteins and the 
tumoral status of the tissue was recorded (table 8 for NGAL and table 9 for MMP-9). 
 
  








Figure 24: NGAL and MMP-9 immunostaining of healthy and tumoral mammary 
glands 
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Table 6: NGAL expression determined semi-quantitatively by immunohistochemical 
staining in tumoral cells 
 
Final score (FS) Healthy Benign tumor Malignant tumor 
Negative (0-2) 8 (61.5%) 0 0 
Weakly positive (3-6) 5 (38.5%) 5 (45.5%) 8 (25%) 




Table 7: MMP-9 expression determined semi-quantitatively by immunohistochemical 
staining in tumoral cells 
 
Final score (FS) Healthy Benign tumor Malignant tumor 
0-2 11 (84.6%) 0 0 
3-6 2 (15.4%) 7 (63.6%) 9 (28.1%) 




Table 8: Differences in NGAL expression between healthy samples and benign or 
malignant tumor samples 
 
 Healthy Benign tumor Malignant tumor 
Negative (0-2) 8 0 0 












Table 9: Differences in MMP-9 expression between healthy samples and benign or 
malignant tumor samples 
 
 Healthy Benign tumor Malignant tumor 
Negative (0-2) 11 0 0 




Sensitivity: 1  
 Specificity: 0.85 
p<0.0001 
Sensitivity: 1  
Specificity: 0.85 
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Table 10: Differences in NGAL expression between benign and malignant mammary 
gland tumors in dogs 
 
 Benign tumor Malignant tumor 
Weakly Positive (3-6) 5 8 
Strongly Positive (7-12) 6 24 
p=0.1845  
Sensitivity: 0.75 / Specificity: 0.45 
 
 
Table 11: Differences in MMP-9 expression between benign and malignant mammary 
gland tumors in dogs 
 Benign tumor Malignant tumor 
Weakly Positive (3-6) 7 9 
Strongly Positive (7-12) 4 23 
p=0.0422  
Sensitivity: 0.72 / Specificity: 0.64 
 
 
2.3.3. Correlation between NGAL and MMP-9 expression and the 
malignant/benign tumoral status 
 
The NGAL expression could not be significantly correlated with the malignant or benign 
status of the tumor (table 10). Even though malignant tumors tended to have a stronger 
staining than the benign ones, the Fisher test gives a non statistically significant result 
(p=0.18). 
 
However, MMP-9 expression seems to be significantly correlated with the malignancy status 
of the gland tumor (table 11). However, both the sensitivity and the specificity remain 
moderate (sensitivity = 72% and specificity = 64%). 
 
2.3.4. Expression level and other prognostic factors 
 
For both proteins, their expression could not be significantly associated with the histological 
type of the malignant tumors. Concerning the histological grading of the tumors, NGAL’s 
expression could not be correlated with the grade. Differences in MMP-9 expression between 
grade I and grades II or III were not proven significant. The small number of samples, 
especially for grade III (n=4) is an obstacle to the statistical analysis. However, if grade II and 
III are grouped together, there is a significant difference in MMP-9 expression between grade 
I and grades II-III (p=0.044, table 12).  
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Table 12: MMP-9 expression according to histological grade of malignant tumors 
 
Histological Grade I II III 
Weakly positive 4 (50%) 2 (14.3%) 0 (0%) 
Strongly positive 4 (50%) 12 (85.7%) 4 (100%) 
The difference between grade I and grade II and III grouped together is significant (p=0.044) 
Sensitivity: 0.89 / Specificity: 0.50 
 
No significant correlation was found between the expression of the two proteins and the age 
of the patient, the number of tumors, the neutered status, the survival time, and the lymph 
node metastasis status. 
 
2.3.5. Correlation between NGAL and MMP-9 expression in mammary 
gland tissues 
 
Because NGAL and MMP-9 are both efficient tissue biomarker of mammary gland tumor 
disease in humans, and because they have been shown to form a complex and to interact with 
each other, especially as NGAL protects MMP-9 from degradation, the correlation between 
the expression of the two proteins was investigated (figure 25). 
 
Spearman correlation test showed that the expression of the two protein are highly correlated 


























Figure 25: Correlation between MMP-9 and NGAL expression in mammary glands 
considering the whole cohort (healthy and tumoral samples)  
 




It is worth noting that 36/56 (64%) of the samples belonged to the same category (negative, 
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3.  DISCUSSION 
 
 
3.1. Production of the MMP-9 antibody: optimization of the protocol 
 
The first serious problems encountered in the production of the antigen started at the steps of 
protein expression and purification. A small scale expression had been performed in order to 
determine the best conditions for the expression protocol. The results obtained indicated that 
an incubation at 37°C for  9 hours after IPTG induction was the optimal conditions, resulting 
in a massive expression of the MMP-9-Dist.  
 
However, several problems occurred at this stage: 
- Another protein (about 4kDa heavier than MMP-9-Dist) was massively expressed by 
the BL21 bacteria during incubation.  
- This contaminant protein became problematic during the protein extraction step, when 
it was observed that it could bind very effectively to the nickel charged sepharose and 
contaminated the elution samples. 
- Furthermore, the overall binding efficiency of the protein extraction procedure was 





Figure 26: SDS-PAGE after protein extraction with the Ni2+ charged sepharose 
according to the first protocol 
- Large scale expression conditions: 37°C for 9 hours after IPTG induction. 
Protein extraction conditions: 6M urea, 0.5M NaCl, binding at room temperature. 
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3.1.1. Contaminant protein 
 
The contaminant protein was noticed to be absent in the no-induction samples and was highly 
expressed after IPTG induction when large scale expression was done at 37°C for 9 hours, 
suggesting a leaky expression or post-translational modifications of the recombinant protein. 
The later hypothesis is strengthened by the fact that it also showed very weakly positive for 
the his-tag when tested by Western Blot with an anti-his antibody. 
To solve this issue, temperature and time were modified during large scale expression in order 
to verify if they impacted the expression of MMP-9-Dist and of the contaminant protein. 
After multiple tries, it was found that changing the large scale expression conditions from 9 
hours at 37°C to 24 hours at 25°C cut down the yield of the recombinant MMP-9-Dist protein 
by about half but also induced an extremely low expression of the contaminant protein. It was 
decided to use these new conditions for the rest of the study. 
 
3.1.2. Binding efficiency during chromatography 
 
To increase the low efficiency of the protein binding by the charged sepharose beads, 
probably due to the protein’s three dimensional structure which may hide the histidine-tag, 
stronger denaturing conditions (particularly by changing the buffers concentration in urea, in 
NaCl, their pH or temperature) were explored.  in particular its concentration in urea, in NaCl, 
its pH or its temperature. An interesting improvement when the urea was increased from 6M 
to 8M and when the NaCl concentration was doubled from 0,5M to 1M was obtained. A small 
increase was also noticed when the binding step was performed at 4°C. By trying these three 
conditions together, the binding efficiency was greatly improved. 
 
By combining this new protein extraction protocol with the optimized large scale expression 













Figure 27: SDS-PAGE after protein extraction with the Ni2+ charged sepharose with the 
modified protocol of large scale expression and chromatography binding 
Large scale expression conditions: 25°C for 24 hours after IPTG induction. 
Protein extraction conditions: 8M urea, 1M NaCl, binding at 4°C. 
Note the good efficiency of the binding as the eluted samples are rich in MMP-9-Dist. The contaminant protein 
is very poorly expressed and MMP-9-Dist is the major component in the samples. 
 
3.1.3. Impact on immunization 
 
These two issues highly affected the yield and purity rate of the produced protein used for the 
prime-injection and the first booster injected to the mice. With the optimized expression and 
extraction conditions, it was possible to produce large amount of high purity rate antigen for 
the following boosters. 
 
 
3.1.4. Prospect to establish a home-made MMP-9 sandwich ELISA test 
 
Because of the difficulties experienced during the purification of MMP-9-Dist, it was not 
possible to harvest enough antigens to immunize both mice and rabbits. As a sandwich ELISA 
assay requires two different antibodies that originated from two different species it was not 
possible to make it with only the home-made mouse antibody. 
 
After the issues concerning the antigen purification have been resolved, enough antigens were 
produced to allow immunization of two rabbits. However the delay needed for the rabbits to 
produce the antibody did not allow us to harvest the antibody and establish a home-made 
sandwich ELISA test before the end of the study.  
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3.2. Expression of NGAL in the urine and serum 
 
3.2.1. Limits and reproducibility 
 
• Representativity of the samples 
 
The aim of this study was to create a preliminary methodological study of the evaluation of 
the NGAL expression in the urine and blood samples of female dogs suffering from 
mammary gland tumors. Though the number of blood samples (28 MMT samples and 14 
healthy samples) was consistent enough, the low number of urine samples (8 MMT samples 
and 5 healthy samples) that were tested is the main limit of this preliminary study. As the 
results obtained seemed encouraging, it would be interesting to repeat this assay on a much 
larger number of urine samples. 
 
• Unreliable standard curve 
 
The original aim of this assay was to determine the exact concentration of NGAL in the 
different samples by comparing their OD values to a standard curve established using a set of 
recombinant NGAL standards.  
 
However it was difficult to use this standard curve to intrapolate the NGAL concentration in 
the samples, mainly for two reasons: 
- The reproducibility of the standard curve was moderate. Whereas the values found for 
clinical samples was very stable from one assay to another, it was not the case for the 
standard samples as differences up to about 25% could be noted from one ELISA test 
to another. 
- The standard curve was not linear. It is possibly due to the continuous loss of proteins 
during serial dilutions. Attempts were made to dilute the recombinant NGAL in PBS 
containing 5% skim milk rather than in PBS. However, results were barely improved. 
Low retention tips and microcentrifuge tube can be used to avoid the trace amount 
protein remains in plastic wares.  
 
• Reproducibility of the assays 
 
Because of the number of blood samples (n=42) being higher than the number of triplicated 
wells available on one ELISA plate, all samples could not be assayed on the same plate. 
However, the assays were repeated two times and the high similarity found in the measured 
ODs showed that the inter-assays bias was neglectable. 
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3.2.2. Serum and urine NGAL concentrations as markers of mammary 
gland tumor affection 
 
Even though serum NGAL concentrations tended to be higher in dogs suffering from a MMT 
than in healthy controls, the difference was not big enough to be significant, unlike the results 
found in human breast cancer. However, it must be noted that even in assays carried on 
human patients, the difference of the serum NGAL concentrations, though significant, was not 
very important. Provatopoulou et al for instance, found an average NGAL concentration in 
serum of DCIS (ductal carcinoma in situ) patients of 80.0 ng/ml (+/- 22.5) , and in serum of 
IDC (invasive ductal carcinoma) patients equal to 87.4 ng/ml (+/- 28.1), these concentrations 
being barely higher than in healthy controls (70.7 ng/ml +/- 17.4).  Considering the narrow 
difference of the two mean concentrations, and the relatively large standard deviations, a very 
large number of both cancerous and healthy samples would be required to prove the 
significance of the increase. Furthermore, the significant result obtained after application of a 
cut-off value confirms that NGAL could be an interesting diagnostic biomarker. 
 
In correspondence with the findings made in human patients, NGAL urinary concentrations 
were significantly correlated with malignant mammary tumor in the sample panel. These 
results suggest that NGAL could be a valuable urinary biomarker of cancer status in female 
dogs. However as mentioned earlier, it would be interesting to investigate this on a larger 
scale with a bigger number of samples and to study its correlation with other factors such as 
lymph node metastasis status, disease-free survival time or histological grade for example, 
which was not possible here due to the small quantity of samples. 
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3.3. Expression of NGAL and MMP-9 in mammary tissues 
 
3.3.1. Optimization of the protocol 
 
The main conditions that have been tested are: 
- Antigen retrieval: power of the microwave and duration. Power was tested from 600 to 
1000 watts, 800 watts seemed to be the best condition as higher power sometimes 
caused degradation of the fragile tissue sections. For similar reasons, the duration 
selected was 20 minutes. 
 
- Blocking: the first reagents used to block were the commercial ones from Dako™’s 
kit. It was found to be slightly less effective than 3% H2O2 and 5% goat serum as the 
use of these two reagents seemed to give lower backgrounds. 
 
- Primary antibody dilution and duration: many different dilutions have been tested 
(from 1:50 to 1:800). Increased dilutions affected the strength of the positive staining 
negatively. The optimal dilutions provide correct staining intensity and allow to 
minimize the antibody consumption; they were 1:400 and 1:150 for NGAL and MMP-
9 IHC, respectively. Also the following application durations have been tried: 
o at room temperature: 1 hour, 2 hours, 4 hours 
o at 4°C: overnight 
For both antibody, an incubation of two hours at room temperature, as the staining 
was slightly better than one hour, and similar to the longer durations, was retained. 
 
- DAB dilution and duration were the hardest conditions to optimize. During the first 
trials, three different dilutions (1:100, 1:250, 1:500) were assessed. The reaction was 
stopped after 30 seconds and the slide was briefly observed under microscope, and 
gradually DAB was added every 30 seconds for evaluating the revelation step. When 
no improvement in the intensity of the positive signal was noted, or when the 
background started to lose its clarity, the precedent DAB conditions (dilution and 
exposure duration) were retained. These steps had to be repeated several times before 
decision was taken to use 1:250 dilution for 2 minutes 15 seconds for NGAL and 3 
minutes for MMP-9. 
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3.3.2. Limits and reproducibility 
 
• Representativity of the tumor samples 
 
The aim of this study was set to evaluate the expression of the two proteins and not the exact 
quantification of their expression in mammary gland tumor; the number of samples was 
voluntarily restricted. However, it must be pointed that the proportion of tumor types is not 
representative of the epidemiology of mammary tumor pathology in dogs: benign tumors 
represent only 26% of the total number of samples, much lower than the real proportion. The 
small number of benign tumors analyzed (11) also impacted the statistical analysis and it 
would be interesting to test more samples. Furthermore, the low number of samples in each 
sub-category of different prognostic factors unabled us to make any conclusion about the 
eventual relation between the protein's expression level and these factors. 
 
• Representativity of the healthy samples 
 
Unlike the other studies performed on MMP-9 IHC, it was not possible to get normal 
mammary glands after euthanasia of dogs showing no palpable mammary gland masses. For 
the healthy controls, glands that were normal as diagnosed by histological examination from 
dogs that had undergone full mastectomy were used. The healthy controls are thereby healthy 
glands from dogs suffering from another mammary gland tumor. As known, the different 
mammary glands are heavily linked, in particular by the aterious/veinous and lymphatic 
networks. The existence of a mammary gland tumor on one mammae may also impact the 
MMP-9 or NGAL expression in healthy glands of another mammae. This could explain that 
the present results for MMP-9 expression are slightly different from ones reported in earlier 
studies. Even though, the expression in the healthy samples remained in majority negative, 
and only two of them showed low positive MMP-9 expression, whereas healthy samples were 
all negative in the assays performed by Hirayama et al in 2002. 
 
• Reading and scoring relevancy 
 
The slide reading and scoring were performed by two different observers. When the grading 
was different, the final score was discussed until both viewers agreed on a compromise. 
However, the two observers were not expert pathologists, and as IHC scoring is a complicated 
and somewhat subjective technique, the small experience of the viewers might have 
sometimes affected the relevancy of the scoring. 
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3.3.3. MMP-9 and NGAL as tissue markers of mammary gland tumors 
 
• MMP-9 as a marker of mammary gland tumor affection, malignancy status and 
histological grades 
 
The MMP-9 expression was a valuable tissue marker in the detection of mammary gland 
tumoral cells. In line with the studies previously performed by Hirayama et al (2002) and 
Santos et al (2012), it was also confirmed in the present study that canine MMP-9 expression 
in the tissue was significantly correlated not only with the tumoral status, but also with the 
malignancy status of the tumor.  
Furthermore, the MMP-9 expression has significantly differed between tumors of grades I and 
tumirs of grade II and III. Out of the three groups, grade I samples showed the lowest MMP-9 
expression but the difference with grade II was not significant, probably because of the low 
number of samples from each category of histological grade. 
Unlike the recent findings of Santos and coworkers, the MMP-9 expression failed to relate to 
any other prognostic factors. The low number of lymph node metastasis positive samples (5) 
and the recentness of the biopsies (half of the tumors were excised less than a year ago) were 
obstacles in the demonstration of MMP-9 expression’s correlation with metastasis or decrease 
of survival time. 
• NGAL expression in correlation with cancer disease status  
This is the first study to investigate the expression of canine NGAL in mammary gland tumor 
tissues. The assays show, in accordance with the results found on human patients by Bauer et 
al in 2008, that canine NGAL expression is significantly increased in tumoral tissue compared 
to healthy controls. However, the difference of NGAL expression between benign and 
malignant tumors was not significant and, unlike Bauer et al,  no correlation between NGAL’s 
expression and prognostic factors such as lymph node metastases status, or poor histological 
grade was found. The lack of significance may inherit from the low number of samples with 
known positive lymph node metastases status (5), or with the low number of histological 
grade I (8) and III (4) tumors. It would be interesting to perform immunohistochemistry on a 
very large number of tumor samples in order to have enough samples for each subcategory of 
commonly used prognostic factors. 
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3.4. Future prospects 
 
In a next future, Chung Hsing University’s Graduate Institute of Microbiology and Public 
Health will aim to investigate the expression of MMP-9 in urine and blood samples by using a 
home-made sandwich ELISA system using the antibodies produced in this study. Two rabbits 
were immunized at the end of this study. Once their serum shows a satisfying antibody titer,  
it will be attempted to establish a home-made sandwich ELISA protocol to evaluate the 
expression of MMP-9 in the blood and urine samples of female dogs suffering from 
mammary gland tumors.  
An assay to detect the MMP-9/NGAL complex in the urine or blood will also be attempted, as 
it was showed in human breast cancer that the complex of the two proteins was a very 
interesting marker of breast cancer status and prognostic factors (Provatoupoulou et al., 2009). 
Using the home-made canine NGAL antibody as coating antibody and the home-made canine 
MMP-9 one as detecting antibody could give interesting results. 
The significant increase in NGAL expression in urines suggest that if studies performed on a 
larger number of samples tend to confirm this observation, NGAL could be a valuable marker 
by a non-invasive technique of mammary gland tumor diagnosis. However, it would serve 
better as an exclusion test as the specificity is much higher than the sensitivity.  A larger 
number of samples would also mean it would be possible to investigate the possible 
correlation between NGAL and prognostic factors such as histological grade or lymph node 
metastases. 
The results obtained in the immunohistochemical assays are encouraging.  It shows not only 
that NGAL and MMP-9 are interesting tissue markers of mammary gland tumor diseases but 
it also suggest that, in agreement with the findings made in human medicine (Fernàndez et al., 
2005), NGAL and MMP-9 may possibly play an interesting role in canine tumor progression, 
particularly MMP-9 since it was correlated with histological type and malignancy status. 
If more studies confirm the role of NGAL and MMP-9 in tumors, a pertinent question is –
could therapeutic inhibition of these proteins slow down tumor progression, and if so, how 
could they be targeted therapeutically? Currently, there are no specific inhibitors of NGAL 
(Chakraborty et al., 2012). However matrix metalloproteinase inhibitors (MMPIs) have been 
developed as therapeutic drugs against cartilage and bone breakdown in rheumatoid arthritis 
(Ahles et al., 1986). MMP-9 activation and expression involves many steps (such as gene 
transcription, RNA translation, secretion of the zymogen, activation of the zymogen and 
degradation) and most of them are modulable throughout pharmacological intervention. Many 
different MMPI have thereby been developed and some have been tested in breast cancers. 
Marimastat pre-clinical studies for example were associated with a significant reduction in 
number and size of metastatic foci in treated versus control animals (Wojtowicz-Praga et al., 
1997). BAY 12-9566 is another potent inhibitor of MMP-9 (as well as MMP-2 and -3) and 
induced tumor growth inhibition against human breast tumor xenografts (Nozaki et al., 1998). 
It must be noted however that despite the fact that the enthusiasm for the use of MMPIs to 
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treat cancer motivated a large implication from pharmaceutical industry, the first clinical trials 
results were not as encouraging (Pavlaki et al., 2003). 
Furthermore, canine mammary gland tumors and human breast cancers share many 
similarities. They share the same histological origins, the same types of regional and general 
metastatic extensions, a similar age of appearance (proportionally compared to the life 
expectancy of the two species).  It is also the most common type of cancer found in both 
species and carcinoma is the main histological type (Hill et al., 2005). The fact that the 
present MMP-9 and NGAL immunohistochemical results share similarities with those found 
in human medical research may suggest the use of canine mammary gland tumor as a 
spontaneous model for human breast cancers in the investigation of therapeutic tools through 
modulation of the MMP-9 and NGAL activities. Currently, NGAL and MMP-9 are mostly 
tested on mice, but dogs show several advantages compared to the murine models: the gene 
homology between dogs and humans is higher and the gene families implicated in tumoral 
lesions of the mammary gland in dogs and humans have been showed to be highly similar 
(Uva et al., 2009). Unlike laboratory mice, dogs also share the same environment as humans 
and are thereby under the impact of the same environmental carcinogenous factors. 
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Mammary gland tumors represent one of the most studied group of tumors in canine 
veterinary research, mostly because of its high prevalence. The investigation of proteins that 
are overexpressed in tumoral cells is essential as not only can they sometimes be used as 
biomarkers, but they may also give interesting therapeutic solutions if they are known to have 
pro-cancerous effects. 
We inspired ourselves from the studies made in human medicine, which have shown several 
times an undeniable correlation between the expression of both matrix metalloproteinase 9 
(MMP-9) and neutrophil gelatinase associated lipocalin (NGAL) and the cancerous status. We 
have aimed to evaluate the expression of the two proteins in the same types of samples as 
those studied from human patients (urine, blood and mammary gland tissue samples). 
Serum and urinary concentrations of canine NGAL from mammary gland tumor patients were 
evaluated for the first time by home-made sandwich ELISA assay while its tissue expression 
was evaluated by immunohistochemistry using home-made rabbit antibody. This is also the 
first study reporting the production and use of home-made anti canine-MMP-9 antibody for 
immunohistochemical assays.  
The NGAL and MMP-9 expressions were correlated in mammary gland tissues, and both 
were shown to be significant tissue markers of tumoral status. Furthermore, MMP-9 was 
shown to be correlated with some prognostic factors such as malignancy status or histological 
grade. Furthermore, serum and urinary NGAL concentrations were higher in dogs suffering 
from malignant mammary tumor than in control dogs. 
These results are similar to the findings in human breast cancer research and confirm the 
similarities between the mammary gland cancers between the two species. They also suggest 
that matrix metalloproteinase inhibitors (or possibly NGAL inhibitors) could be interesting to 
investigate as therapeutic agents against canine mammary gland tumor progression and 
metastasis. 
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APPENDIX 1: PROTOCOLS 
 
 
Protocol 1: RNeasy® mini kit for RNA extraction (Qiagen®) 
Cell lysis 1. Extract 0.2 g of testicule tissue with a surgical blade 
2. Pound the tissue using a mortar and pestle and pour liquid nitrogen to 
obtain cell lysis 
3. Resuspend with 200 µl of PBS 
Re-suspension 4. Put the 200 µl of sample in a new tube and add 500 µl of RLT Buffer and 
700 µl of 70% ethanol 
Lysis 5. Add 200µl of PD2 Buffer and mix gently (do not vortex) 
Neutralization 6. Add 300µl of PD3 Buffer and mix gently (do not vortex) 
7. Centrifuge at 14,000 x g for 3 minutes 
RDNA Binding 8. Place the PD Column in a 2 ml Collection Tube 
9. Add the supernatant from step 6 to the PD Column and centrifuge at 
14,000 x g for 30 seconds and discard the flow-through 
Wash 10. Add 400 µl of W1 Buffer into the PD Column 
11. Centrifuge at 14,000 x g for 30 seconds and discard the flow-through 
12. Add 600 µl of Wash Buffer (ethanol added) into the PD Column 
13. Centrifuge at 14,000 x g for 30 seconds and discard the flow-through 
14. Centrifuge at 14,000 x g again for 3 minutes to dry the column matrix 
RDNA Elution 15. Transfer the dried PD Column to a new centrifuge tube and add 50 µl of 
DEPC treated water into the center of the column matrix and let stand 2 
minutes 
16. Centrifuge at 14,000 x g for 2 minutes to elute the RNA 
The different buffers are kit contents and their exact composition is not detailed in the handbook. 
DEPC treated water: ddH2O treated with 0.1% diethylpyrocarbonate and incubated overnight at 37°C 
prior to being autoclaved. This treatment inactivates RNase enzymes and protects the extracted RNA 
from degradation.  
 
 
Protocol 2: Superscript III Supermix Kit for Reverse Transcription (Invitrogen™) 
Mixing 1. In a PCR tube mix: 
-5 µl of RT Reaction mix 
-1 µl of RT Enzyme mix 
-2 µl of RNA sample 




2. Set the PCR machine for 1 cycle: 
-25°C for 10 minutes (enzyme activation) 
-50°C for 30 minutes (priming and extension) 
-85°C for 5 minutes (terminating) 
-chill on ice 
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Protocol 3: Amplification of the insert by PCR (Phusion™ DNA polymerase kit) 
Mixing 1. In a PCR tube mix: 
-5 µl of 5xBuffer  
-2 µl of 2.5µM dNTPs mix (Protech™) 
-2.5 µl of 5µM F-Primer 
-2.5 µl of 5µM R-Primer  
-0.0625 µl of Phusion™ DNA polymerase 
-1 µl of template cDNA 
-11.75 µl of ddH2O 
Amplification 2. Set the PCR machine as follows: 
-98°C for 30 seconds (denaturing) 
-35 cycles: 
        -98°C for 10 seconds (denaturing) 
        -62°C for 30 seconds (annealing) 
        -72°C for 30 seconds (extension) 




Protocol 4: 1% agarose gel 
Gel preparation 1. Mix: 
-0.3 g of agarose 
-30 ml of TAE Buffer 
2. Heat with a microwave oven until it boils 
3. Add 2 µl Nucleic Acid Stain 
4. Wait for the gel to cool down and solidify at room temperature 
5. Insert 5 µl of sample in the well  
Gel running 6. Run horizontal electrophoresis at 100V for 25 minutes 
Revelation 7. Use an UV transilluminator to visualize the fluorescent DNA bands 
TAE Buffer: Tris-Acetate EDTA 




Protocol 5: pET-24a(+) and cDNA insert digestion by Nde I and Xho I (New England 
Biolabs® kit) 
Mixing 1. In a PCR tube mix: 
-6 µl of ddH2O 
-2 µl of NE Buffer 4 10x 
-2 µl of BSA 10x  
-1 µl of Nde I 
-1 µl of Xho I  
-8 µl of pET-24a(+) or cDNA sample 
Digestion 2. Leave in 37°C incubator for 2 hours  
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Protocol 6: Gel DNA Fragments Extraction Kit (Geneaid™) 
Gel dissociation 1. Excise the agarose gel containing the relevant DNA and remove any 
extra agarose to minimize the size of the gel slice (maximum 300 mg) 
2. Transfer the gel slice to a 1.5 ml microcentrifuge tube 
3. Add 500 µl of DF Buffer and mix by vortex 
4. Incubate at 60°C for 15 minutes and cool down to room temperature 
DNA binding 5. Transfer 800 µl of the sample mixture to the DF Column furnished in the 
kit 
6. Centrifuge at 6,000 g for 30 seconds and discard the flow-through 
Washing 7. Add 400 µl of W1 Buffer 
8. Centrifuge at 6,000 g for 30 seconds and discard the flow-through 
9. Add 600 µl of Wash Buffer and let stand for 1 minute 
10. Centrifuge at 6,000 g for 30 seconds and discard flow-through 
11. Centrifuge again for 3 minutes to dry the column matrix 
DNA Elution 12. Add 50 µl of Elution Buffer and let stand for 2 minutes 
13. Centrifuge at 6,000 g for 2 minutes to elute the purified DNA 




Protocol 7: Ligation (New England Biolabs® kit) 
Mixing 1. In a PCR tube mix: 
-96 µl of ddH2O 
-2 µl of NE T4 Ligase Reaction Buffer 10x 
-4 µl of DNA insert 
-4 µl of plasmid 
-1 µl of NE T4 DNA Ligase 
Ligation 1. Leave at 4°C overnight 
NE T4 Ligase Reaction Buffer: 50 mM Tris-HCl, 10 mM MgCl2, 10 mM Dithiothreitol, 1 mM ATP. 
 
 
Protocol 8: Preparation of competent cells 
Bacteria growth 1. Grow a 5 ml culture of Top10® E.coli overnight 
2. Refresh the overnight culture (1 ml) in 100 ml of LB broth 
3. Incubate the new culture at 37°C, 250rpm and check optical density 
(OD) at 595nm regularly until OD is greater than 0.4 
4. Centrifuge during 10 minutes at 4000 g and 4°C and discard supernatant 
Charging the 
bacteria 
5. Add 50 ml of 0.1M CaCl2 and resuspend the bacteria pellet  
6. Centrifuge during 10 minutes at 4000 g and 4°C and discard supernatant 
7. Add 40 ml of 0.1M CaCl2, resuspend the pellet and leave on ice for 1 
hour 
8. Centrifuge during 10 minutes at 4000 g at 4°C and discard supernatant 
Stocking 9. Add 3 ml of 0.1M CaCl2 with 15% glycerol and resuspend the pellet 
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Protocol 9: Transformation 
Mixing 1. Add 1µl of plasmid DNA into 50 µl of competent cells inside a 
microcentrifuge tube 
2. Leave on ice during 30 minutes 
Heat shock 3. Place the sample in a 42°C water-bath for 90 seconds 
4. Chill on ice immediately after 
 
 
Protocol 10: Colony selection by antibiotic resistance 
Bacteria growth 1. Add 450µl of LB broth in the sample that just received the heat-shock 




3. Centrifuge at 4000 g for 2 minutes and discard 400 µl of supernatant 
4. Resuspend the pellet with the remaining supernatant 
5. Streak 10 µl of the culture on a LB agar plate containing kanamycin (50 
µg/ml) 
6. Incubate at 37°C for 18 hours 
Verification 7. Select colonies and analyze by plasmid digestion, PCR, or sequencing 
LB Broth: 4 g NaCl + 2 g yeast extract + 4 g tryptone + 400 ml ddH2O 
 
 
Protocol 11: High-Speed Plasmid Mini Kit (Geneaid ®) 
Harvesting 1. Transfer 1.5 ml of the cultured bacterial cells to a microcentrifuge tube 
2. Centrifuge at 14,000 x g for 1minute and discard supernatant 
Re-suspension 3. Add 200µl of PD1 Buffer (RNase) and resuspend the pellet 
Lysis 4. Add 200µl of PD2 Buffer and mix gently (do not vortex) 
Neutralization 5. Add 300µl of PD3 Buffer and mix gently (do not vortex) 
6. Centrifuge at 14,000 x g for 3 minutes 
DNA Binding 7. Place the PD Column in a 2 ml Collection Tube 
8. Add the supernatant from step 6 to the PD Column and centrifuge at 
14,000 x g for 30 seconds and discard the flow-through 
Wash 9. Add 400 µl of W1 Buffer into the PD Column 
10. Centrifuge at 14,000 x g for 30 seconds and discard the flow-through 
11. Add 600 µl of Wash Buffer (ethanol added) into the PD Column 
12. Centrifuge at 14,000 x g for 30 seconds and discard the flow-through 
13. Centrifuge at 14,000 x g again for 3 minutes to dry the column matrix 
DNA Elution 14. Transfer the dried PD Column to a new centrifuge tube and add 50 µl of 
Elution Buffer into the center of the column matrix and let stand 2 
minutes 
15. Centrifuge at 14,000 x g for 2 minutes to elute the DNA 
PD1 Buffer, PD2 Buffer, PD3 Buffer, W1 Buffer, Wash Buffer and Elution Buffer are kit contents 
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Protocol 12: Small scale expression 
Colony growing 1. Pick 1 isolated BL21 colony from the LB agar + kanamycin plate 
2. Insert in a 5 ml LB broth + kanamycin culture medium 
3. Incubate at 37°C and 250rpm overnight 
Culture refresh 4. Transfer 350 µl of the culture in a new 7 ml LB broth + kanamycin 
culture medium and incubate at 37°C and 250rpm 
5. After 2 hours of incubation, test the optical density of the medium using 
clean LB broth as standard. Repeat every 30 minutes until OD is greater 
than 0.6 
Induction 6. Retrieve 1 ml of the culture medium, centrifuge at 4000 g during 5 
minutes and store at -20°C (no induction control) 
7. Add 0.8M IPTG at 1/1000 final concentration 
8. Incubate at 37°C and 250rpm 
Harvesting 9. After 3h, retrieve 1 ml of the culture medium, centrifuge at 4000 g 
during 5 minutes and store at -20°C (T3h sample) 




Protocol 13: Large scale expression 
Colony growing 1. Pick 1 isolated BL21 colony from the LB agar + kanamycin plate 
2. Insert in a 10 ml LB broth + kanamycin culture medium 
3. Incubate at 37°C and 250rpm overnight 
Culture refresh 4. Pour the whole culture in 200 ml LB broth + kanamycin culture medium 
and incubate at 37°C and 250rpm 
5. After 2 hours of incubation, test the optical density of the medium using 
clean LB broth as standard. Repeat every 30 minutes until OD is greater 
than 0.6 
Induction 6. Retrieve 1 ml of the culture medium, centrifuge at 4000 g during 5 
minutes and store at -20°C (no induction control) 
7. Add 200 µl (1/1000) of 0.8M IPTG  
8. Incubate at 25°C and 250rpm for 24 hours 
Harvesting 9. Retrieve 1 ml of the culture as a “post-expression control” and centrifuge 
the rest of the culture at 4000 g during 15 minutes 
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Protocol 14: Protein extraction 
Bacteria lysis 1. Resuspend the bacteria pellet obtained at the end of the large scale 
expression protocol with 10 ml of binding buffer (1/20 volume of 
refreshed bacteria) 
2. Freeze (-80°C) and thaw (quick 37°C) 
3. As soon as the frozen bacteria pellet is liquidized, add 200 µl of  
lysozyme (1/50 of buffer volume) and leave in a 37°C water-bath during 
20 minutes 
4. Do two more freeze-thaw cycles. Viscous should occur. 
 
Sonication 5. Sonicate on ice to break down the chromosome DNA (work for 10s / 
pause for 10s, total action period: 5 minutes) 
Harvesting of 
the native form 
6. Centrifuge at 6,000 g at 4°C for 15 minutes 
7. The supernatant contains the native protein, while the insoluble protein is 
trapped in the pellet. Retrieve the supernatant 
For pellet, see step 9 




9.  Resuspend the pellet from step 6 with 10 ml of Urea binding buffer and 
repeat steps 5 and 6 to solubilize the denatured protein 
Lysozyme: 50 mg/ml 
Binding buffer: 50 ml of 0.5M Tris-HCl + 50 ml of 5M NaCl + 0.34 g of Imidazole in 500 ml of 
ddH2O. 
Urea Binding buffer: 50 ml of 0.5M Tris-HCl + 1050 ml of 5M NaCl + 0.34 g of Imidazole + 240 g of 
urea in 500 ml of ddH2O. 
  
- 103 - 
 
Protocol 15: His-tagged protein extraction (Chelating Sepharose Fast Flow of 
BioProcess™ Media family) 
Column 
preparation 
1. Transfer 1 ml of sepharose slurry to a new column and drip off the 
preserve medium 
2. Use 5-time column volume of ddH2O to wash the sepharose 
Discard flow-through 
3. Charge the sepharose by adding 2-time volume of 0.1M NiSO4 
Keep the column at room temperature for 5 minutes and drip off 
The sepharose should become green 
4. Add 5-time column volume of ddH2O and drip off 
5. In order to equilibrate the column, add 5-time column volume of the 
same binding buffer that was used in extraction (Binding Buffer for 
native proteins and Urea Binding Buffer for denatured proteins  
Keep at room temperature for 5 minutes and drip off 
The column is ready for purification 
His-tagged 
protein binding 
6. Pour the supernatant obtained in the extraction protocol (save 100 µl as a 
control prior to purification) in the column 
7. Rock for 2 hours at 4°C and drip off 




8. Add 10-time column volume of Washing Buffer 1 (Urea Washing Buffer 
1 for denatured proteins) into the column, rock for 5 minutes and drip 
off, keep the washing flow-through (W) 
9. Check the protein content in the flow through by using Bio-Red Protein 
Dye reagent 
Repeat washes with Washing Buffer 2 (Urea Washing Buffer for 




10.  Add 1 ml of Elution Buffer 1 (Urea Elution Buffer 1 for denatured 
proteins) and rock for 5 minutes 
Collect flow-through in new tube (E1) and check protein content 
Repeat until protein content is very low (E2) 
11. Repeat step 11 with Elution Buffer 2 (Urea Elution Buffer 2) until 
protein content is very low (E3, E4, E5..) 
Regeneration 12. Add 1 ml of Regenerating Buffer into the column, rock for 5 minutes and 
collect flow-through (R1) 
Repeat (R2) 
Bio-Red Protein Dye: 10 µl of flow through in 100 µl of 1x Bradford reagent 
Binding Buffer: 50 ml of 0.5M Tris-HCl + 50 ml of 5M NaCl + 0.34 g of Imidazole) in 500 ml of ddH2O 
Urea Binding Buffer: 50 ml of 0.5M Tris-HCl + 100 ml of 5M NaCl + 0.34 g of Imidazole + 240 g of urea in 
500 ml of ddH2O 
Washing buffer 1(20 mM): 50 ml of 0.5M Tris-HCl + 50 ml of 5M NaCl + 0.68 g of Imidazole in 500 ml of 
ddH2O 
Urea Washing buffer 1(20 mM): 50 ml of 0.5M Tris-HCl + 100 ml of 5M NaCl + 0.68 g of Imidazole + 240 g of 
urea in 500 ml of ddH2O 
Washing buffer 2(50 mM): 50 ml of 0.5M Tris-HCl + 50 ml of 5M NaCl + 1.70 g of Imidazole in 500 ml of 
ddH2O 
Urea Washing buffer2 (50 mM): 50 ml of 0.5M Tris-HCl + 100 ml of 5M NaCl + 1.70 g of Imidazole + 240 g of 
urea in 500 ml of ddH2O 
Elute buffer 1 (100 mM): 10 ml of 0.5M Tris-HCl + 10 ml of 5M NaCl + 0.68 g of Imidazole in 100 ml of 
ddH2O 
Urea Elute buffer 2 (400 mM): 10 ml of 0.5M Tris-HCl + 20 ml of 5M NaCl + 2.72 g of Imidazole + 49 g of 
urea in 100 ml of ddH2O 
Regeneration buffer:  9.3 g of EDTA + 14.61 g of NaCl + 1.42 g of Na2HPO4 + 20 g of NaOH in 500 ml of 
ddH2O – pH = 7.4 
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Protocol 16: SDS PAGE 
Running gel 
preparation 
1. Prepare the running gel (10 ml) by following the recipe shown in table 
13  
2. Pour the solution in the get casting form but leave 3cm for the stacking 
gel 
3. Layer the top of the gel with 70% ethanol solution to remove the bubbles 
and avoid the top of the gel to dry 




5. Prepare the stacking gel (5 ml) by following the recipe shown in table 13 
6. Pour the solution on top of the running gel 
7. Insert combs and wait 20 minutes for the gel to polymerize 
Sample 
preparation 
8. Mix the sample 2:1 with the sample buffer 
9. Heat the sample in a boiling water-bath for 5 minutes 
Running the gel 10.  Clamp in the gel and fill both buffer chambers with Gel Running Buffer 
1. Pipet the samples into the wells and keep one well for the molecular 
weight standards  
11. Run the gel at 80V for 25 minutes and then 120V for 70 minutes 
Revelation 12. Retrieve the gel and stain it for 1 hour with Brilliant Blue Staining 
Solution 
13. Destain several times with Destaining Buffer until the gel is clear 
Running Buffer: 6.32 g Tris + 4 g Glycine + 1 g SDS + 1L ddH2O 
Brilliant Blue Staining Solution: 0.25 g Brilliant Blue R + 45 ml methanol + 45 ml ddH2O + 10 ml 
acetic acid 
Destaining Buffer: 300 ml methanol + 100 ml acetic acid + 600 ml ddH2O 
 
 
Table 13: Recipe for the running gel at 12.5% and the stacking gel at 4% used in SDS-
PAGE 
 Running gel 12.5%  
- pH8.8 (ml) 
Stacking gel  4%  
- pH6.8 (ml) 
ddH2O 3.7 4.3 
Acrylamid 40% 0.6 3 
1.5M Tris 0.6 0 
1M Tris 0 2.5 
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Protocol 17: Protein purification by transfer on PVDF membrane 
Protein 
separation 
1. Run each sample of eluate from the extraction protocol on a SDS-PAGE 




2. Prepare the PVDF membrane: 
     -soak the membrane 2 minutes in 100% ethanol 
     -soak the membrane in ddH2O for 3 minutes 
     -soak the membrane in the Blot Transfer Buffer for 15 minutes 
3. Transfer the gel to the PVDF membrane using the same technique as 




4. Stain the membrane with Ponceau S and as soon as the band 
corresponding to MMP-9-Dist is visible, cut it from the membrane and 
destain it in ddH2O 
5. Insert the destained membrane piece in a microcentrifuge tube and add 
300 µl of Elution Buffer 
6. Vortex during 10 minutes, retrieve and discard the pieces of membrane 
Elution Buffer: 2% SDS, 1% Triton-X in Tris-HCl 50 mM, pH 9.5. 
 
 
Protocol 18: Acetone precipitation 
Precipitation 1. Add cold (-20°C) acetone at a 4:1 volume ratio in the sample tube 
and store at -20°C for 1 hour 
2. Centrifuge at 10000 g and 4°C for 15 minutes 
3. Carefully discard the supernatant and add washing solution to 
clean the protein pellet 
4. Centrifuge at 10000 g and 4°C for 10 minutes 
5. Carefully discard supernatant 
6. Air-dry for 2 minutes under the hood 
Resuspension 7. Add PBS and resuspend the pellet until the protein is dissolved 
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Protocol 19: Western Blot 
SDS-PAGE 1. Run the samples on a SDS-PAGE 
Transfer 
preparation 
2. Precut two Whatman™ 3MM filter papers and one nitrocellulose 
membrane (7x9cm) 
3. Soak the membrane and filter paper in Blot Transfer Buffer  
Assemble 4. In a try filled with Blot Transfer Buffer, assemble in the black side 
of a cassette in the following order: 
     -black side of cassette 
     -fiber pad 
     -soaked filter paper 
     -the gel from the SDS-PAGE 
     -soaked nitrocellulose membrane 
     -soaked filter paper 
     -fiber pad 
     -white side of cassette 
Transfer 5. Insert the cassette into the electrode module, with the black side of 
the cassette next to the cathode 
6. Place the electrode module in the buffer tank and fill the tank with 
Blot Transfer Buffer 
7. Run electrophoresis at 250mA for 3 hours 
Detection 8. Retrieve the membrane and block it in 10 ml of 5% skim milk for 1 
hour at room temperature 
9. Add 1st antibody diluted in 5% skim milk 
Incubate for 3 hours while shaking at room temperature 
10. Wash 6 times for 5 minutes per wash with PBS-T  
11. Add 2nd antibody diluted in 5% skim milk and incubate 1 hour, 
shaking at room temperature 
12. Wash 6 times for 5 minutes per wash with PBS-T 
Revelation 13. Reveal the results by ECL (enhanced chemiluminescence)  after 
addition of VisGlow plus Chemiluminescent substrate 
Blot Transfer Buffer (1L): 800 ml ddH2O + 200 ml methanol + 5.81 g tris + 2.93 g glycine 
PBS-T (1L): 1L PBS + 1 ml Tween-20 
5% skim milk (50 ml):  2.5 g Skim milk Difco™ + 50 ml PBS-T 
 
 
Protocol 20: Ammonium sulfate precipitation 
Retrieval  
of fraction 1  
(0-40%) 
1. Add an equal volume of ammonium sulfate until a 40% saturation 
is obtained 
Incubate 2 hours at room temperature 
2. Centrifuge at 10,000 g for 10 minutes 
Retrieve supernatant and put it in a new tube for 50% precipitation 
3. Resuspend the pellet in PBS (Fraction 1) 
Retrieval of 
fraction 2  
(40-50%) 
4. Add ammonium sulfate in the retrieved supernatant until a 50% 
saturation is obtained 
Incubate 2 hours at room temperature 
Verification 5. Run both fraction 1 and fraction 2 on a SDS-PAGE to verify which 
one contains the most antibody 
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1. Transfer 2 ml of Protein G sepharose in a Biorad™ column 
2. Wash column with 10  ml of Wash Buffer 1 
Immunoglobulin 
Binding 
3. Add the rabbit serum and rotate for 30 minutes at 4°C 
Run the column 
4. Repeat step 3 with the flow-through 
Wash 5. Wash the column with 10 ml of Wash Buffer 1 
6. Wash the column with 10 ml of Wash Buffer 2 
Antibody 
Elution 
7. Elute the antibody off the Protein G beads with 2 ml of Glycine 
Buffer and collect the eluted protein in a tube containing a 15% 
final fraction volume of Neutralization Buffer (Fraction 1) 
8. Repeat 3 times (Fraction 2, 3 and 4) 
9. Wash the column with 10 ml of Regeneration Buffer 
Verification 10. Check the samples on 10% SDS-PAGE, combine the peak 
fractions and test the antibody by western blotting 
Wash Buffer 1: 0.135M NaCl, 100 mM Tris-HCl, pH8.0 
Wash Buffer 2: 10 mM Tris-HCl, pH 8.0 
Glycine Buffer: 100 mM glycine, pH3.0 
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1. Dilute 13 µl of rabbit anti-NGAL antibody in 10.4 ml of ELISA 
Coating Buffer (1:800 dilution) 
2. Fill all 96 wells of the ELISA plate with 100 µl of the solution 
3. Close the plate, cover it with a wet tissue and put it in a plastic bag 
to avoid drying 
4. Incubate at 37°C for 1 hour 
5. Wash all wells 5 times with PBS 
Blocking 6. Add 150 µl of Blocking Buffer in each well 
7. Repeat step 3 and leave at room temperature for 1 hour 
8. Empty the wells but do not wash 
Add antigen 9. Insert standard 1-8 and standard PBS in triplicates  
10. Dilute 20 µl of each clinical sample into 380 µl of PBS and fill 3 
wells (triplicate allow more reliable results) with 100 µl of this 
solution 
11. Repeat step 3 and incubate at 4°C overnight 
12. Wash all wells 5 times with PBS 
Detecting 
antibody 
13. Make a 1:3000 dilution of the anti-NGAL mouse antibody in 5% 
skim milk 
14. Apply 100 µl in  each well 
15. Repeat step 3 and incubate at 37°C for 1 hour 
16. Wash all wells 5 times with PBS 
Enzyme-linked 
antibody 
17. Make a 1:5000 dilution of anti-mouse Fc section goat antibody in 
5% skim milk 
18. Apply 100 µl in each well 
19. Repeat step 3 and incubate at 37°C for 1 hour 
20. Wash all wells 10 times with PBS 
Substrate 
addition 
21. Add 100 µl of TMB in each well 
22. Close the plate and leave 5 minutes in darkness 
23. Neutralize the reaction by adding 50 µl of 2M H2SO4 in each well 
Revelation 24. Read the optical density of all the wells by spectrophotometry 
(wave length: 420-620nm) 
ELISA Coating Buffer: 1.59 g of Na2CO3 + 2.93 g of NaHCO3 in 1L ddH2O 
Blocking Buffer: StartingBlock™ Blocking buffer 
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1. Insert slides in 100% xylene solution at 50°C for 15 minutes two 
times 
2. Dry the slides under the hood for 10 minutes 
3. Soak the slides in 100% ethanol for 3 minutes two times 
4. Soak the slides in 95% ethanol for 3 minutes  
5. Soak the slides in 75% ethanol for 3 minutes 
6. Soak the slides in 50% ethanol for 3 minutes 
Antigen 
retrieval 
7. Preheat Citrate Buffer with microwave until it boils 
8. Soak the slides in the Citrate Buffer and microwave at 800 watts 
for 20 minutes 
9. Wait 10 minutes for the Citrate Buffer to cool down using a room 
temperature water-bath 
Blocking 10. Shake the slide dry and circle the area of interest with a Dako pen 
Be careful not to let the tissue dry out 
11. Wash the slides 3 times with ddH2O 
12. Apply 3% H2O2 for 10 minutes 
13. Wash the slides 3 times with ddH2O 
14. Apply 5% Goat serum for 30 minutes 
15. Wash the slides 3 times with ddH2O 
Primary 
antibody 
16.  Apply 300 µl of diluted primary antibody at the desired dilution 
(1:400 for NGAL, 1:150 for MMP-9) for 2 hours 
17. Wash the slides 5 times with ddH2O 
Secundary 
antibody 
18. Apply Secondary antibody for 30 minutes 
19. Wash the slides 3 times with ddH2O 
Substrate 20. Apply 1:250 diluted DAB at the desired duration (2 minutes and 15 
seconds for NGAL and 3 minutes for MMP-9)  
21. Wash the slides 3 times with ddH2O 
Counterstaining 22. Apply Mayer’s hematoxylin for 30 seconds 
23. Wash the slides 3 times with ddH2O 
24. Soak the slides in tap water for 1 minute 
Dehydration 
and mounting 
25. Dry the slides at 50°C overnight 
26. Mount the slides  
27. Let the slides dry for 2 hours before reading 
Citrate Buffer:  18 ml of 0.1M Citric acid + 82 ml of 0.1M Sodium citrate + 900 ml ddH2O pH6.0 
5% Goat serum: 0.5 ml of normal goat serum diluted in 9.5 ml of PBS 
Primary antibody diluant: Dako REAL™ antibody diluant with background reducing components  
Secundary antibody: Dako REAL™ EnVision™ HRP Rabbit/Mouse  
DAB: Dako REAL™ DAB + Chromogen (x50) and Dako REAL™ Substrate buffer 
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APPENDIX 2: CANINE MMP-9 SEQUENCE 
 
 
Figure 28: Canine MMP-9 Gene sequence 
The translated amino-acids are marked as well as the location of the primers that were chosen 
 APPENDIX 3: PET-24A(+) MAP
Figure 
The kanamycin resistance gene as well as the unique restriction sites are marked. The black bold arrow marks 











29: Map of pET-24a(+) vector 
figure 8. 
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Figure 30: Concentration estimation of the antigen by SDS-PAGE 
The standards used are 3 different concentration of BSA (100, 250 and 500 µl/ml). Image J software can 
calculate the intensity of the signal after circling the area of interest. Note that the protein in samples is very 






Figure 31: Determination of the antigen's signal intensity compared to the BSA 
standards 
Image J software draws the color intensity curve. The area corresponding to the BSA and the antigen are then 
determined and the software calculates their AUC, which is proportional to the concentration. 
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Table 14: Immunization scheme of the three mice with MMP-9-Dist 
 
Mouse 1 
 Priming 1st Boost 2nd Boost 3rd Boost 
Day 1 11 22 31 
Concentration 143 µg/ml 390 µg/ml 760 µg/ml 240 µg/ml 
Volume 300 µl 140 µl 140 µl 300 µl 
Antigen mass 43 µg 54.6 µg 106 µg 80 µg 
Purity 99% 99% 99% 99% 
 
Mouse 2 
 Priming 1st Boost 2nd Boost 3rd Boost 
Day 2 11 22 31 
Concentration 361 µg/ml 154 µg/ml 680 µg/ml 410 µg/ml 
Volume 250 µl 300 µl 140 µl 200 µl 
Antigen mass 90 µg 46 µg 95 µg 82 µg 
Purity 70% 70% 99% 99% 
 
Mouse 3 
 Priming 1st Boost 2nd Boost 3rd Boost 
Day 2 11 22 31 
Concentration 602 µg/ml 262 µg/ml 810 µg/ml 370 µg/ml 
Volume 150 µl 300 µl 120 µl 220 µl 
Antigen mass 90 µg 78 µg 97 µg 81 µg 





























FRENCH SUMMARY OF THE STUDY 
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Les tumeurs de la glande mammaire représentent le type de tumeur le plus fréquemment 
rencontré chez les chiennes, avec une incidence affectant plus de 25% des femelles non 
stérilisées. Cette incidence est plus de trois fois supérieure à celle du cancer du sein observée 
en médecine humaine. De nouvelles études sont constamment effectuées afin de trouver de 
nouvelles façons de diagnostiquer, d'évaluer, de suivre et de traiter cette pathologie chez ces 
deux espèces. 
La matrix metalloprotéinase 9 (MMP-9), aussi décrite sous le nom de gelatinase B, est un 
contributeur majeur dans la dégradation protéolytique de la matrice extra-cellulaire lors de 
l'invasion des tissus adjacents par une tumeur. En médecine humaine, il a été montré que 
l'expression de cette protéine dans le sérum, l'urine et le tissu mammaire de patientes atteintes 
de cancer du sein était fortement augmentée. De nombreux auteurs ont donc suggéré 
l'utilisation de la MMP-9 comme bio-marqueur de cette pathologie. 
La neutrophil gelatinase-associated lipocalin (NGAL) a été isolée pour la première fois en 
1992 en tant que glycoprotéine de petite taille, fixée de manière covalente à la MMP-9 dans 
des granulocytes neutrophiles humains.  Il fut montré plus tard que la NGAL  pouvait inhiber 
la dégradation de la gelatinase B, augmentant ainsi l'activité de cette dernière.  Il fut par 
ailleurs démontré que cette protéine aussi pouvait être utilisée comme bio-marqueur du cancer 
du sein dans le sérum, l'urine et le tissu mammaire. 
En médecine vétérinaire, la corrélation entre l'expression de ces deux protéines et les tumeurs 
mammaires n'a que très peu été étudiée. Seuls quelques projets rapportent l'utilisation 
d'anticorps anti MMP-9 humaine dans des études immuno-histochimiques et démontrent que 
son expression  était significativement corrélée à plusieurs facteurs pronostiques tels que la 
malignité, le grade histologique ou la présence de métastases dans les nœuds lymphatiques. 
En revanche, aucune étude n'a été menée sur la NGAL canine. 
Cette étude avait pour but d'utiliser des anticorps spécifiques de la NGAL et de la MMP-9 
canines afin de mettre au point une méthode permettant d'évaluer le niveau d'expression de 
ces deux protéines dans plusieurs échantillons biologiques de patients atteints de tumeur 
mammaire.  L'expression sérique et urinaire de la NGAL a été analysée grâce à un test ELISA 
fait maison, tandis que les niveaux d'expression de la NGAL et de la MMP-9 dans des coupes 
histologiques de tumeurs mammaires ont été évalués par immuno-histochimie. 
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1. MATERIEL ET METHODE 
 
1.1. Production d'anticorps anti MMP-9 canine 
 
 
- Extraction de l'ARN total et transcription en ADN 
L'ARN total de cellules issues de tissu testiculaire canin a été isolé après lyse à l'azote liquide 
et extraction à l'aide d'un kit (Qiagen®’s RNeasy®). L'ARN total a ensuite été transcrit en 
ADNc par transcription inverse grâce au kit Superscript™ III Supermix de Invitrogen™. 
 
- Production d'un insert codant pour la MMP-9-Dist 
Après analyse de l'hydrophobicité de la MMP-9 canine, il a été décidé de produire comme 
antigène la partie distale de la protéine (nommée MMP-9-Dist dans cette étude) correspondant 
environ aux 200 derniers acides aminés. La fraction d'ADN codant pour cette partie distale a 
été amplifiée par PCR en utilisant les amorces suivantes :   
5’-AACATATGGCCATCGCGGAGATCAGGAACTAC-3’ 
        et 5’-AACTCGAGGCACTGCAAAATGTCAAAG-3'.  
 
Le produit obtenu a été vérifié par électrophorèse sur gel d'agarose à 1% et présentait une 
taille compatible avec celle de la portion d'ADN désirée, soit environ 550pdb. 
 
- Préparation du vecteur 
Le vecteur utilisé était le plasmide pET-24a de Novagen™. pET-24a possède un gène de 
résistance à la kanamycine et permet notamment d'ajouter une étiquette de six résidus 
d'histidine à une extrémité de la protéine. Le plasmide a d'abord été digéré par deux enzymes 
de restriction (NdeI et XhoI) et le résultat de cette digestion a été vérifié par électrophorèse 
sur gel d'agarose à 1%. L'insert codant pour la MMP-9-Dist a lui aussi été digéré à l'aide des 
mêmes enzymes et du même protocole. 
 
- Liaison et transformation 
La liaison entre l'insert et le vecteur a été obtenue à l'aide de l'ADN ligase en incubant le 
mélange une nuit à 4°C. Le plasmide ainsi généré a été inséré dans des Escherichia coli One 
Shot® Top10 d'Invitrogen®. Cette transformation a été réalisée en mélangeant les bactéries 
préalablement chargées positivement par du CaCl2, avec le plasmide et en leur faisant subir un 
choc thermique à 42°C pendant 30 secondes afin de forcer l'internalisation du plasmide dans 
la bactérie. 
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- Sélection et screening des colonies bactériennes 
Une première sélection a été réalisée en utilisant comme milieu de culture un milieu LB 
enrichi en kanamycine, afin de ne sélectionner que les bactéries ayant acquis un gène de 
résistance et donc le plasmide. Un premier screening a été appliqué en amplifiant par PCR, à 
partir de bactéries isolées re-suspendues, la portion d'ADN codant pour la MMP-9-Dist. Un 
second test de screening a été réalisé en extrayant les plasmides des bactéries à l'aide du kit 
High Speed Plasmid Mini Kit de Geneaid®, et en étudiant les produits obtenus après digestion 
par les enzymes NdeI et XhoI. Les produits de ces deux tests de screening ont été vérifiés par 
électrophorèse sur gel d'agarose à 1% et coïncidaient avec les résultats attendus. 
Afin de confirmer que les bactéries avaient efficacement intégré la portion d'ADN codant 
pour la MMP-9-Dist, un échantillon a été envoyé pour séquençage au laboratoire Mission 
Biotech de Taipei. La séquence extraite était identique à celle de MMP-9-Dist. 
 
- Transfert du plasmide chez un hôte expresseur 
Les E.coli top10 ne pouvant que répliquer le plasmide et non exprimer l'insert s'y trouvant, les 
plasmides ont été extrait à l'aide du kit de Geneaid®, et ont été réinsérés chez un nouvel hôte 
(E.coli BL21 de Biomol®) en répétant à l'identique le protocole utilisé pour la première 
transformation. Les bactéries ayant efficacement intégré le plasmide ont ensuite été 
sélectionnées en utilisant un milieu de culture enrichi en kanamycine. 
 
- Expression de l'antigène 
Après avoir rafraichi une culture à un ratio de 1/20 dans un grand volume de milieu LB (200-
500 ml), celle-ci a été incubée à 37°C jusqu'à ce que sa densité optique à 595nm soit 
supérieure à 0.6A. L'expression a ensuite été induite par de l'IPTG à 0.8 mM et a été réalisée à 
25°C pendant 24 heures. 
 
- Extraction de la MMP-9-Dist recombinante 
Les bactéries ont été lysées à l'aide de lysozyme (30 minutes à 37°C) et de cycles de chocs 
thermiques (-80°C et +37°C) avant de subir 10 minutes de sonication aux ultrasons puis une 
centrifugation. La MMP-9-Dist recombinante étant en grande majorité exprimée sous sa 
forme dénaturée, il a fallu répéter les étapes de sonication et de centrifugation en utilisant un 
tampon riche en urée (8M) et en NaCl (1M) afin de rendre la forme dénaturée soluble. 
La protéine a ensuite été extraite à l'aide de colonnes de chromatographie contenant GE 
Healthcare’s Chelating Sepharose™ qui, une fois chargées par du Ni2+, montrent une très 
forte affinité pour les résidus histidine et donc en particulier pour l'étiquette histidine présente 
sur la MMP-9-Dist recombinante. L'imidazole permettant de réduire cette affinité, des 
premiers nettoyages avec des concentrations de 20 mM et 50 mM d'imidazole ont été réalisés 
- 120 - 
 
afin de se débarrasser des contaminants. La MMP-9-Dist a ensuite été éluée en augmentant la 
teneur en imidazole à 400 mM. 
 
- Purification de la MMP-9-Dist recombinante 
Les protéines présentes dans les éluats de l'étape d'extraction ont été séparées par SDS-PAGE 
et transférées sur une membrane PVDF puis teintes avec du Ponceau S. Dès que la MMP-9-
Dist fut visible, elle a été repérée, découpée et le fragment de membrane inséré dans un 
microtube contenant une solution tampon d'élution. Après 10 minutes de vortex, le fragment 
de membrane a été enlevé et l'échantillon a subi une précipitation à l'acétone afin de laver la 
protéine des contaminants de la solution d'élution. L'échantillon a donc été mélangé à de 
l'acétone froid (-20°) et a été maintenu à -20°C pendant 1 heure afin que la MMP-9-Dist 
précipite. Après centrifugation, l'acétone a été retirée et le culot a été re-suspendu dans du 
PBS. 
 
- Estimation de la concentration de l'antigène 
L'échantillon obtenu ainsi que différentes concentrations de BSA (bovine serum albumin) ont 
été séparés par SDS-PAGE. L'intensité du signal obtenu pour MMP-9-Dist a pu être comparée 
à celles des standards de BSA afin d'évaluer, à l'aide du logiciel Image J, la concentration en 
MMP-9-Dist dans l'échantillon. 
 
- Immunisation et retrait des antigènes 
Après vérification par Western-Blot que la protéine était bien la MMP-9-Dist recombinante 
(par mise en évidence de la présence d'une étiquette d'histidines), l'antigène a été mélangé 
avec du Freund's adjuvant complete sigma (ratio 1:1) puis injecté par voie intrapéritonéale à 3 
souris. Une primo-injection et trois rappels ont été réalisés. Avant chaque injection, 500 µl de 
sang étaient prélevés depuis le sinus rétro-orbital. Un dernier échantillon de sang a été prélevé 
une semaine après le dernier rappel puis centrifugé et le sérum obtenu a été utilisé comme 
anticorps polyclonal de la MMP-9 canine. 
 
1.2. Production et purification d'anticorps anti NGAL canine 
 
 
- Production de NGAL recombinante 
La production de la NGAL recombinante n'a pas été réalisée lors de ce projet mais lors d'une 
étude préliminaire réalisée au sein du Graduate Institute of Microbiology and Public Health de 
Chung Hsing University (Taichung, Taiwan). L'ARN total a été extrait d'un homogénat de 
tissu mammaire canin et a été transcrit en ADNc. La portion codante pour la NGAL a été 
amplifiée par PCR, insérée dans un vecteur pET-32b puis intégrée dans des E.coli BL21. La 
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NGAL recombinante a été exprimée à 16°C pendant 24 heures après induction par de l'IPTG, 
puis extraite par chromatographie sur des colonnes contenant du sepharose chargé au nickel. 
Trois souris et trois lapins ont été immunisés. 
 
- Purification des anticorps anti-NGAL 
Lors de cette étude, le sérum des lapins et des souris a été récupéré et afin de purifier et 
d'enrichir l'anticorps en vue de l'IHC (Immunohistochimie), deux méthodes de purification 
ont été utilisées. Dans un premier temps, une précipitation au sulfate d'ammonium a permis de 
ne conserver que la fraction de protéines qui précipitait à une saturation en sulfate 
d'ammonium inférieure à 50%. Les anticorps ont ensuite été purifiés par chromatographie à 
l'aide de protéines G qui se lient avec une forte affinité au fragment Fc des anticorps. Une 
solution de glycine à pH 3.0 a permis ensuite de défaire cette liaison et de récupérer les 
anticorps après avoir éliminé les contaminants. 
 
1.3. Mise au point d'un test sandwich ELISA pour doser la NGAL 
 
 
- Echantillons étudiés 
En vue d'étudier le niveau d'expression de la NGAL dans le sérum et dans l'urine de chiennes 
malades, 28 échantillons de sang et 8 échantillons d'urine de chiennes atteintes de tumeur 
mammaire maligne ont été analysés dans cette étude. Les témoins, provenant de chiennes 
saines, étaient au nombre de 14 pour les échantillons sanguins et de 5 pour ceux d'urine. 
 
- Optimisation du protocole 
L'anticorps anti-NGAL provenant du sérum d'un lapin a été utilisé comme anticorps de 
capture à un taux de dilution de 1:800. Les 96 puits de la plaquette ELISA ont été remplis 
avec 100 µl et incubés 1h à 37°C. Entre chacune des étapes suivantes, les puits ont été rincés 
cinq fois avec du PBS-T. 
150 µl de solution tampon pour blocage ont ensuite été ajoutés dans chaque puits et 
l'ensemble a été laissé 1h à température ambiante. 
20 µl de chaque échantillon clinique ont ensuite été dilués dans 380 µl de PBS et pour chaque 
échantillon, trois puits ont été remplis avec 100 µl du mélange obtenu, puis la plaque ELISA a 
été incubée à 4°C pendant une nuit. 
L'anticorps anti-NGAL provenant du sérum d'une souris a ensuite servi d'anticorps de 
détection. 100 µl d'anticorps dilué à 1:3000  ont été utilisés avant d'incuber à 37°C pendant 
1h. 
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Un anticorps anti-Fc-souris, conjugué à une peroxydase et dilué à 1:5000 dans 100 µl ont 
ensuite été ajoutés. Après 1h d'incubation à 37°C et de nombreux lavages au PBS-T, 100 µl 
de TMB ont été ajoutés dans chaque puits et laissés pendant 5 minutes avant que la réaction 
ne soit stoppée par un ajout de 50 µl de H2SO4. La densité optique des 96 puits a ensuite été 
mesurée (420-620nm). 
 
1.4. Mise au point d'un protocole d'immunohistochimie en vue de doser la 
NGAL et la MMP-9 dans le tissu mammaire 
 
 
- Nature et origine des échantillons 
43 échantillons ont été obtenus lors d'exérèses chirurgicales réalisées à l'hôpital vétérinaire de 
l'Université de Chung Hsing sur des chiennes atteintes de tumeur mammaire. 32 des tumeurs 
étudiées étaient malignes (20 carcinomes complexes, 11 carcinomes simples, 1 
carcinosarcome) et 11 étaient bénignes (8 tumeurs bénignes mixtes, 2 adénomes complexes, 1 
adénome simple). Nos essais ont été réalisés sur des sections de 4µm de ces tissus ainsi que 
sur 13 sections de glandes mammaires saines. 
 
- Optimisation du protocole d'IHC 
Les lames ont d'abord été déparaffinées à l'aide de deux bains successifs de 15 minutes dans 
du xylène à 50°C puis réhydratées progressivement par bains de 3 minutes dans des solutions 
d'éthanol de moins en moins concentrées (100% deux fois de suite, 95%, 75% puis 50%). 
Les antigènes ont ensuite été rendus détectables en chauffant les lames dans une solution 
tampon citratée pendant 20 minutes à 800 watts au four à micro-ondes. Après refroidissement 
à température ambiante, la section de tissu a été entourée avec un feutre Dakopen. Entre 
chacune des étapes suivantes, les lames ont été rincées avec  de l'eau distillée. 
Afin de minimiser le marquage non spécifique, deux méthodes de blocage ont été utilisées : 
tout d'abord les peroxydases endogènes ont été inhibées par une solution à 3% de H2O2 
pendant 10 minutes, puis une solution de sérum de chèvre à 5% a été appliquée sur les lames 
pendant 30 minutes. Le premier anticorps a ensuite été ajouté, dilué à 1:400 pour la NGAL et 
1:100 pour la MMP-9, et laissé en contact avec le tissu pendant 2 heures. 
L'anticorps dilué Dako REAL™ EnVision™, couplé à une peroxydase a ensuite été ajouté puis 
laissé 30 minutes avant l'ajout de DAB (diaminobenzidine) dilué à 1:250. Le temps de mise 
en contact du tissu et de ce substrat était de 2 minutes 15 secondes pour la NGAL et de 3 
minutes pour la MMP-9. 
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Une contre coloration à l'hématoxyline de 30 secondes a été réalisée avant de plonger les 
lames dans de l'eau plate pendant 1 minute. Les lames ont ensuite été séchées une nuit à 50°C 
puis montées. 
 
- Contrôles positifs et négatifs 
Contrôle positif : Pour chaque nouvelle série, une lame que l'on savait être fortement positive 
était incluse. S'il était jugé que la qualité du marquage obtenu sur cette lame était moins bonne 
que d'habitude, toutes les lames de la série étaient écartées et l'opération répétée. 
 
Contrôle négatif : Chaque nouvelle série contenait une lame de contrôle négatif pour laquelle 
l'anticorps primaire était remplacé par du sérum pré-immun. 
 
- Lecture des lames et score de marquage 
Pour chaque lame, les paramètres suivants étaient analysés : existence et spécificité du 
marquage, distribution cellulaire, homogénéité à travers la section. De plus, l'expression des 
protéines était évaluée de manière semi-quantitative en jugeant : 
 
 -le score d'intensité, allant de 0 (pas de marquage) à 3 (équivalent au contrôle positif). 
 -le score de proportion de cellules tumorales positives, pouvant être 1 (<10%), 2 (11-
 50%), 3 (50-80%) ou 4 (>80%). 
 
Le score final (FS) d'une lame était ensuite égal au produit de ces deux scores. L'échantillon 
était ainsi considéré négatif (FS entre 0 et 2), faiblement positif (FS entre 3 et 7) ou fortement 
positif (FS entre 7 et 12). Les lames ont été scorées par deux évaluateurs. Lorsque les avis 
étaient différents, le score final était discuté jusqu'à obtention d'un accord.  
 
 
1.5. Analyses statistiques 
 
 
Les tests statistiques utilisés dans cette étude sont le test de Student (avec ou sans la 
correction d'Aspin-Welch selon l'homogénéité des variances), le test exact de Fisher et le test 
de corrélation de Spearman. Tous ont été réalisés à l'aide du logiciel GraphPad™ Prism et 
tout résultat associé à une valeur p<0.05 était considéré comme significatif. 
 
  





2.1. Production d'anticorps anti MMP-9 canine 
 
 
- Capacité à détecter la MMP-9 
Après retrait du sérum des souris immunisées avec la MMP-9-Dist, son aptitude à détecter la 
MMP-9 a été testée par Western blot sur trois échantillons : 
-la MMP-9-Dist recombinante, afin de s'assurer que l'anticorps reconnaissait l'antigène initial 
-la MMP-9 humaine du commerce, afin de tester la capacité de l'anticorps à reconnaitre la 
protéine humaine 
-un homogénat tissulaire de carcinome mammaire, afin de voir si l'anticorps était apte à 
détecter la protéine sur des échantillons cliniques. 
Pour chacun de ces trois essais, l'anticorps a su reconnaître la protéine. 
 
- Evaluation du titre en anticorps du sérum 
Un ELISA a été réalisé en utilisant la MMP-9-Dist recombinante comme antigène et en 
variant le taux de dilution (de 1:100 à 1:3200) des sérums obtenus chez les 3 souris soumises 
à l'immunisation. Le titre était défini comme étant la concentration en anticorps pour laquelle 
la densité optique obtenue était deux fois supérieure à celle du sérum pré-immun. Le sérum 
utilisé pour les essais d'IHC présentait ainsi un titre de 1:5840. 
   
 
2.2. Evaluation du niveau d'expression de la NGAL dans le sérum et l'urine 
par ELISA sandwich  
 
 
- Echantillons de sang 
La moyenne de la densité optique observée chez les chiennes atteintes de tumeur mammaire 
maligne (0.147, n=28) était supérieure à celle observée chez les témoins sains (0.128, n=14) 
mais cette différence n'était pas statistiquement significative (test de Student avec correction 
d'Aspin-Welsh, p=0.116).  
Cependant, l'implémentation d'une valeur seuil à une densité optique de 0.193 (égale à la 
moyenne observée chez les individus sains + 2 écarts-types), montre que les échantillons de 
chiennes malades dépassent plus souvent ce seuil que les échantillons témoins (Test de Fisher, 
p=0.015). 
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- Echantillons d'urine 
La moyenne de la densité optique observée pour les échantillons d'urine de chiennes malades 
(0.097, n=8) était supérieure à celle des témoins sains (0.048, n=5). La différence était 
statistiquement significative (test de Student avec correction d'Aspin-Welsh, p=0.034). A 
noter que l'une des valeurs obtenues chez les chiennes malades a été jugée extrême (0.752) et 
a été ignorée lors du calcul de ces moyennes. 
Ici aussi, l'implémentation d'une valeur seuil (égale à la valeur moyenne observée chez les 








- Efficacité du marquage 
43 sections de glande mammaire tumorale et 13 sections de glande mammaire ne présentant 
pas d'anomalie histologique ont été marquées. Dans la très grande majorité des sections, y 
compris celles de glandes saines, et aussi bien pour NGAL que pour MMP-9, il était possible 
d'observer au moins quelques cellules luminales qui présentaient un marquage positif, 
contrairement aux sections ayant servi de témoins négatifs (utilisation de sérum pré-immun en 
guise d'anticorps primaire) qui ne présentaient aucun signal positif. 
Toutes les sections de glandes tumorales étaient positives, aussi bien à la NGAL qu'à la 
MMP-9. Les niveaux d'expression variaient le plus souvent non pas par la proportion de 
cellules positives (souvent entre 60 et 100%), mais par l'intensité du signal (allant de 1 à 3). 
 
- Corrélation entre le niveau d'expression et le statut cancéreux 
Les échantillons sains étaient dans la grande majorité négatifs à la MMP-9 (85%), sinon 
faiblement positifs (15%). Concernant la NGAL, 62% étaient négatifs et 38% faiblement 
positifs. 
En comparaison, 100% des sections de glandes tumorales étaient faiblement ou fortement 
positives. 
Pour la NGAL, le niveau d'expression est significativement corrélé au statut cancéreux (test 
de Fisher, p=0.001 si l'on compare les sains et les tumeurs bénignes, p=0.0001 si l'on compare 
les sains et les tumeurs malignes). Il en est de même pour la MMP-9 (test de Fisher, p=0.0001 
si l'on compare les sains et les tumeurs bénignes ou les sains et les tumeurs malignes). 
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- Corrélation entre le niveau d'expression et le statut de malignité 
Les sections de tumeurs malignes ont tendance à présenter un niveau d'expression de NGAL 
plus élevé que les témoins, mais la significativité n'a pu être démontrée (test de Fisher, 
p=0.13). La MMP-9 en revanche, est exprimée plus fortement en cas de tumeur maligne qu'en 
cas de tumeur bénigne (test de Fisher, p=0.04). 
 
- Corrélation entre le niveau d'expression et d'autres facteurs pronostiques 
Le niveau d'expression de la MMP-9 a tendance à augmenter avec le grade histologique des 
tumeurs malignes. En regroupant les grades II et III, l'expression au sein de ce groupe est 
significativement supérieure à celle observée dans les échantillons de grade I (test de Fisher, 
p=0.04). Ce n'est pas le cas pour la NGAL. 
De plus, aucune corrélation n'a pu être démontrée comme significative entre le niveau 
d'expression des deux protéines et d'autres facteurs tels que : 
 -l'âge des patients 
 -le nombre de tumeurs 
 -le statut stérilisé ou non 
 -le temps de survie 
 -la présence de métastases dans les nœuds lymphatiques 
  
- Corrélation entre les deux protéines 
La NGAL étant capable de se lier de manière covalente à la MMP-9 et d'inhiber ainsi la 
dégradation de cette dernière, il semblait judicieux de voir si les niveaux d'expression de ces 
deux protéines étaient corrélés. Le test de corrélation de Spearman démontre que les deux 
protéines ont effectivement tendance à avoir des variations parallèles (p=0.0001) et ont un 
coefficient de corrélation r = 0.67. 
A noter que pour 64% des échantillons analysés, les résultats (négatif, faiblement positif ou 
fortement positif) obtenus pour les deux protéines étaient identiques. 
 
 





3.1. Optimisation du protocole de production des anticorps anti-MMP-9 
 
 
- Protéine contaminante 
Une étape d'expression préliminaire de l'antigène à petite échelle par les bactéries BL21 a été 
réalisée afin de déterminer les conditions optimales d'expression. Les conditions ainsi 
déterminées (37°C pendant 9 heures) présentaient cependant un inconvénient. En effet, une 
protéine légèrement plus grosse que la MMP-9-Dist était également produite de manière 
importante par les bactéries. Cette protéine était d'autant plus gênante qu'elle se liait elle aussi 
aux billes de sepharose lors de l'extraction et qu'il était donc impossible de s'en défaire. 
Après plusieurs essais à grande échelle, il a été décidé d'opter pour de nouvelles conditions 
d'expression (25° pendant 24 heures), qui diminuaient de moitié la production de MMP-9-Dist 
mais n'entrainaient qu'une expression marginale de la protéine contaminante. 
 
- Efficacité de l'étape d'extraction 
La principale difficulté rencontrée lors de la production de l'antigène concernait l'étape 
d'extraction. En effet, la protéine se liait très peu aux billes de sépharose et rendait son 
extraction très peu efficace lors des premiers essais. Après plusieurs tentatives, il a été décidé 
de modifier la composition de la solution tampon utilisée en augmentant de manière 
importante les conditions dénaturantes (les concentrations en urée et en NaCl ont été 
augmentées respectivement de 6M à 8M et de 0.5M à 1M) et en réalisant l'étape de fixation à 
4°C au lieu de 37°C. 
 
- Impact sur l'immunisation 
Les deux difficultés suscitées ont eu pour conséquence l'utilisation d'une solution antigénique 
peu concentrée (150 µg/ml) et présentant un taux de pureté moyen (70%) lors de la primo-
injection et du premier rappel. Les nouvelles conditions d'expression et d'extraction ont 
cependant permis d'obtenir des solutions très concentrées (400-1000 µg/ml) et très pures 
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3.2. Expression de la NGAL dans l'urine et le sérum 
 
 
- Représentativité de l'échantillon 
Si le nombre d'échantillons sanguins était suffisamment conséquent (n=28), celui 
d'échantillons d'urine était par contre relativement faible (n=8) et ne permet qu'une étude 
préliminaire méthodologique de l'évaluation de l'expression de la NGAL. Les résultats 
obtenus étant encourageants, il serait intéressant de répéter cette étude sur un grand nombre 
d'échantillons. 
 
- Reproductivité des essais 
Le nombre d'échantillons sanguins (n=42 en comptant les témoins sains) ne permettaient pas 
de les tester tous sur une seule plaque ELISA. Cependant, les essais ont été répétés et le biais 
inter-essais a été jugé négligeable. 
 
- Mise au point d'un test sandwich ELISA pour la MMP-9 
Le test ELISA permettant d'évaluer l'expression de la MMP-9 n'a pas pu être mis au point, 
principalement en raison des difficultés rencontrées lors de la production de l'antigène. Celui-
ci n'était pas extrait en quantité suffisante pour immuniser des lapins en plus des souris. Après 
modification des conditions d'expression et d'extraction il a été possible d'immuniser deux 
lapins qui permettront à une étude future de mettre au point un tel test. 
 
- Expression urinaire et sérique de la NGAL et tumeur mammaire 
Le niveau moyen d'expression dans le sang des sujets atteints n'était pas significativement 
supérieur à celui des témoins. Cependant, il est intéressant de noter qu'en médecine humaine, 
cette différence était très faible (Provatopoulou et al, 2009), et qu'un nombre d'échantillons 
suffisamment important serait peut-être capable de rendre cette différence significative. 
L'application d'une valeur seuil montre qu'il semble tout de même y avoir un lien entre le 
statut cancéreux et le niveau d'expression de la protéine. 
Concernant le niveau d'expression urinaire, il a été montré que la différence était significative 
et que l'expression de la NGAL pouvait donc être corrélée au statut cancéreux. Ces résultats 
sont en correspondance avec ceux obtenus en médecine humaine. Cependant, comme il a été 
mentionné précédemment, le faible nombre d'échantillons affaiblit clairement la puissance 
statistique du test et il serait intéressant, à présent que la méthode est au point, de réitérer cette 
étude avec un nombre plus important d'échantillons. 
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3.3. Expression de la NGAL et de la MMP-9 dans le tissu mammaire 
 
 
- Optimisation du protocole 
Les principaux paramètres à avoir été optimisés étaient : 
-la puissance du four à micro-ondes lors de la révélation des antigènes : testée de 600W à 
1000W, la puissance de 800W a semblé offrir le meilleur compromis entre efficacité de 
révélation et faible dégradation du tissu. 
-réactifs de blocage : le sérum de chèvre et l'H2O2 ont été préférés au réactif commercial 
fourni dans le kit Dako™  qui offrait un moins bon contraste. 
-dilution et temps de contact du premier anticorps : lors de l'optimisation du protocole, la 
dilution a été doublée à plusieurs reprises jusqu'à ce que l'augmentation affecte la qualité du 
marquage. Nous avons pu en déduire que les dilutions de 1:400 pour la NGAL et de 1:100 
pour la MMP-9 permettaient d'économiser au maximum les anticorps sans affecter la qualité 
du marquage. De même, divers temps de contact ont été testés (1h, 2h, 4h, une nuit). Nous 
avons opté pour 2h mais ce paramètre n'impactait que très peu le résultat.  
-dilution du DAB et temps de contact : de façon similaire, les temps de contact et la 
concentration du DAB ont été augmentés jusqu'à ce que cela affecte la qualité du marquage 
ou jusqu'à ce que cela n'augmente plus le contraste. 
 
- Limites et reproductibilité 
Représentativité des échantillons : il est intéressant de noter que la répartition des types de 
tumeurs n'est pas représentative de l'épidémiologie de cette affection. Les tumeurs bénignes 
ne représentaient en effet que 26% de nos échantillons. De plus, le faible nombre de tumeurs 
bénignes (n=11) impacte aussi l'étude statistique. Il serait donc intéressant de réitérer 
l'expérience avec un plus grands nombre de tumeurs bénignes. Enfin, le faible nombre 
d'échantillons présents dans chaque sous catégorie de différents facteurs pronostiques ne 
permet pas de conclure quant à une éventuelle corrélation entre les niveaux d'expression et ces 
marqueurs. 
Représentativité des témoins : contrairement aux études déjà réalisées sur la MMP-9 canine et 
son homologue humaine, nous n'avons pas utilisé de glandes saines de patients sains, mais des 
glandes apparemment saines de patients atteints de tumeur mammaire sur une autre mamelle. 
Connaissant le réseau artériel, veineux et lymphatique qui peut relier les mamelles entre elles, 
il n'est pas exclu que la présence d'une tumeur puisse avoir une répercussion sur l'expression 
des protéines dans les mamelles saines. Ceci pourrait notamment expliquer que des résultats 
faiblement positifs ait été obtenu sur des tissus sains, contrairement aux études antérieures.  
Enfin, un autre paramètre pouvant influencer l'exactitude ou la reproductibilité des résultats 
obtenus est la fiabilité du système de score. En plus de l'aspect subjectif de ce système, le 
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score a été déterminé par deux observateurs qui ne sont pas des spécialistes en anatomie 
pathologique (deux vétérinaires dont un actuellement en résidanat d'anatomie pathologique). 
 
- Relation entre l’expression tissulaire de la MMP-9, le statut tumoral et certains 
facteurs pronostiques 
En accord avec ce qui a pu être mis en évidence chez la femme dans les études réalisées par 
Hirayama et al. en 2002 et chez la chienne dans les études de Santos et al. en 2012, nos 
résultats montrent que le niveau d'expression de la MMP-9 dans le tissu mammaire de 
chiennes atteintes de tumeur peut être un bon marqueur de cette pathologie. Son expression 
est aussi impactée par le statut de malignité de la tumeur, ainsi que par son grade histologique 
si cette dernière est maligne. Cependant la différence entre grade I et grade II n'a pu être 
démontrée comme étant significative, probablement en raison du faible nombre d'échantillons 
présents dans ces deux catégories. 
Contrairement aux découvertes récentes de Santos et al., l'expression de la protéine n'a pas pu 
être reliée à d'autres facteurs pronostiques. Le faible nombre de patients ayant présenté des 
métastases (n=5) d'une part et le caractère récent des exérèses (réalisées en 2011 et 2012) 
d'autre part, ont probablement été un obstacle dans l'étude de la corrélation éventuelle existant 
entre la MMP-9 et la présence de métastases ou la baisse du temps de survie. 
A noter qu'il s'agit de la première étude visant à évaluer le niveau d'expression de la MMP-9 
par immunohistochimie avec des anticorps anti MMP-9 canine. En effet, les études réalisées 
précédemment, notamment par Santos et al en 2012, ont été menées avec des anticorps anti 
MMP-9 humaine. 
 
- Expression de la NGAL dans le tissu mammaire de chiennes atteintes de tumeur 
Cette étude est la première à s'être intéressée à l'expression tissulaire de la NGAL dans le cas 
de tumeur mammaire. Nos résultats montrent, en accord avec les découvertes réalisées en 
médecine humaine par Bauer et al en 2008, que le niveau d'expression de la NGAL est 
significativement augmenté en cas de tumeur. Cependant, ces résultats ne permettent pas de 
mettre en évidence un effet du statut malin ou bénin sur cette expression. Aucun autre facteur 
pronostique ne semble impacter le niveau d'expression mais une telle étude nécessiterait un 
nombre beaucoup plus conséquent d'échantillons afin d'être concluante. 
 
- Perspectives 
Dans un futur proche, le Graduate Institute of Microbiology and Public Health de la Chung 
Hsing University de Taichung, Taiwan, se penchera sur la mise en place, à partir de l'antigène 
produit lors de cette étude, d'un test sandwich ELISA apte à évaluer le niveau d'expression de 
la MMP-9 canine dans l'urine et le sérum de chiennes atteintes de tumeur mammaire.  
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Un test ELISA permettant la mise en évidence du complexe MMP-9/NGAL sera aussi réalisé. 
En effet, des études en médecine humaine (Provatopoulou et al., 2009) ont montré que ce 
complexe pouvait être un biomarqueur parfois plus efficace que les protéines étudiées 
individuellement.  
L'augmentation significative du niveau d'expression de la NGAL dans l'urine de chiennes 
atteintes suggère que si une étude réalisée à plus grande échelle tendait à confirmer nos 
résultats, la NGAL pourrait être un biomarqueur intéressant dans le diagnostic non invasif de 
tumeur mammaire. Cependant, au vu de nos résultats préliminaires, un tel test serait plutôt un 
test d'exclusion car sa spécificité semble bien meilleure que sa sensibilité. Un plus grand 
nombre d'échantillons rendrait de plus possible l'étude de la corrélation entre le niveau 
d'expression et les facteurs pronostiques les plus couramment suivis.  
Les résultats obtenus en immunohistochimie sont très encourageants. Ils démontrent que la 
NGAL et la MMP-9 sont d'intéressants marqueurs tissulaires de la pathologie. De plus, en 
s'appuyant sur les résultats obtenus en médecine humaine par Fernandez et al. en 2005, il est 
possible que ces deux protéines soient impliquées dans la progression de ces tumeurs, en 
particulier la MMP-9 pour qui le niveau d'expression a pu être corrélé avec le statut de 
malignité et le type histologique. 
Si d'autres études venaient à confirmer les résultats obtenus lors de nos essais, une des 
problématiques suggérées serait de savoir si l'inhibition de ces protéines pourrait ralentir la 
progression et la dissémination de la tumeur et dans l'affirmative, comment pourrait-elle être 
ciblée de manière thérapeutique. Il n'existe encore aucun inhibiteur thérapeutique de la NGAL 
mais des inhibiteurs de la MMP-9 ont déjà été testés chez la femme. Si les premiers tests 
réalisés sur des modèles murins ont donné des résultats très prometteurs (Wojtowicz-Praga et 
al., 1997), les premiers essais cliniques ont en revanche donné des résultats moins 
encourageants (Pavlaki et al., 2003). 
Enfin, le cancer du sein de la femme et les tumeurs mammaires chez la chienne partagent de 
nombreuses similitudes : une origine histologique similaire, un même type d'extensions 
métastatiques régionales et générales, un âge d'apparition comparable (proportionnellement à 
l'espérance de vie) et de nombreux autres points communs. Il s'agit aussi du type de tumeur le 
plus prévalent chez les deux espèces (Hill et al, 2005). Le fait que les résultats obtenus lors de 
l'évaluation du niveau d'expression de la NGAL et de la MMP-9 soient en accord avec ceux 
obtenus en médecine humaine renforce cette similitude et suggère que les tumeurs 
mammaires de la chienne pourraient éventuellement servir de modèle spontané dans la 
recherche de moyens thérapeutiques agissant via la modulation de l'expression de ces 
protéines. 
  




Les tumeurs de la glande mammaire représentent l'un des groupes de tumeur le plus étudié en 
recherche vétérinaire canine, principalement du fait de son haut niveau de prévalence. Les 
études enquêtant sur les protéines surexprimées en présence de phénomènes cancéreux sont 
essentielles. En effet, non seulement ces dernières peuvent servir de bio-marqueurs dans le 
diagnostic, l'évaluation ou le suivi de ces pathologies, mais elles peuvent aussi parfois offrir 
de nouvelles solutions thérapeutiques s'il est démontré qu'elles présentent des effets favorisant 
la croissance, l'expansion ou la dissémination des tumeurs. 
En s'inspirant des études réalisées en médecine humaine sur la MMP-9 et la NGAL, qui ont à 
plusieurs reprises prouvé une corrélation indéniable entre les niveaux d'expression de ces 
deux protéines et le statut cancéreux, nous avons cherché à évaluer leur niveau d'expression 
dans les mêmes types d'échantillons que ceux étudiées en médecine humaine (sérum, urine et 
tissu mammaire). 
Les niveaux d'expression sérique et urinaire de la NGAL ont été évalués pour la première fois 
à l'aide d'un test sandwich ELISA fait maison tandis que son expression tissulaire a été 
étudiée par immunohistochimie en utilisant des anticorps spécifiques de l'espèce canine. Il 
s'agit également de la première étude décrivant la production et l'utilisation d'anticorps anti 
MMP-9 canine dans des tests immunohistochimiques. 
Nos résultats démontrent une corrélation significative entre l'expression de la NGAL et celle 
de la MMP-9 dans le tissu mammaire et leur niveau d'expression est un marqueur efficace du 
statut tumoral. De plus, l'expression de la MMP-9 a pu être reliée à certains facteurs 
pronostiques tels que la malignité ou le grade histologique. Enfin, il a été montré que 
l'expression de la NGAL dans le sérum et l'urine était plus élevée chez les chiennes atteintes 
de tumeur mammaire. 
Ces résultats sont cohérents avec les découvertes réalisées en médecine humaine, et 
confirment la similarité entre les tumeurs de la glande mammaire de ces deux espèces. 
Connaissant les propriétés de ces protéines (notamment la capacité de la MMP-9 à dégrader la 
matrice extracellulaire, favorisant ainsi l'expansion et la dissémination de la tumeur), ces 
résultats suggèrent par ailleurs que l'utilisation d'inhibiteurs de la MMP-9 (ou éventuellement 
de la NGAL) pourrait être envisagée en tant que possible option thérapeutique contre la 
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TITLE: EVALUATION OF THE EXPRESSION OF MATRIX METALLOPROTEINASE 9 AND 
NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN IN SERUM, URINE AND TUMORAL 
TISSUES OF FEMALE DOGS SUFFERING FROM MAMMARY GLAND TUMORS 
 
ABSTRACT 
In human medicine, it has been shown recently that the level of expression of matrix metalloproteinase-9 
(MMP-9) and neutrophil gelatinase-associated lipocalin (NGAL) in serum, urine, and breast tissue were 
significantly increased in patients with breast cancer and correlated to several prognostic factors. 
In the first part, the author presents the MMP-9 and NGAL as a synthesis of current knowledge on their ability 
to serve as biomarkers of breast cancer in women. 
In the second, the author presents the production of canine MMP9 and NGAL recombinant proteins, the 
production of polyclonal antibodies, and their use in various techniques (ELISA, western blot, 
immunohistochemistry) to assess the level of expression of these proteins in the blood, urine and breast tissue 
of dogs suffering from mammary gland tumors and demonstrate a positive correlation between these proteins 
and the presence of a tumor disease of the mammary gland. 
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TITRE : EVALUATION DE L'EXPRESSION DE LA MATRIX METALLOPROTEINASE 9 ET 
DE LA NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN DANS LE SERUM, L'URINE 
ET LE TISSU TUMORAL DE CHIENNES ATTEINTES DE TUMEURS MAMMAIRES 
 
RESUME 
En médecine humaine, il a été montré récemment que le niveau d'expression de la matrix métalloprotéinase-9 
(MMP-9) et de la neutrophil gelatinase-associated lipocalin (NGAL) dans le sérum, l'urine, et le tissu mammaire 
étaient significativement augmentés chez les patientes atteintes de cancer du sein et étaient corrélés à de 
nombreux facteurs pronostiques.  
Dans une première partie, l'auteur présente la MMP-9 et la NGAL ainsi qu'une synthèse des connaissances 
actuelles portant sur leurs aptitudes à servir de biomarqueurs du cancer du sein chez la femme. 
Dans la seconde, l'auteur présente la production de MMP9 et de NGAL canines recombinantes, la production 
d'anticorps polyclonaux associés, et leur utilisation dans diverses techniques (ELISA, western blot, 
immunohistochimie) permettant d'évaluer le niveau d'expression de ces protéines dans le sang, l'urine et le 
tissu mammaire de chiennes malades et de démontrer ainsi une corrélation positive entre ces protéines et la 
présence d'une affection tumorale de la glande mammaire. 
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